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ABSTRACT
INVESTIGATION OF PHOSPHOSERINE AMINOTRANSFERASE 1(PSAT1) IN
BREAST CANCER PROGRESSION

Stephanie Metcalf
August 23, 2019

This dissertation describes my research into the involvement of
phosphoserine aminotransferase 1 (PSAT1) in breast cancer progression;
specifically, in triple negative breast cancer (TNBC) metastasis and endocrine
resistance in estrogen receptor positive breast cancer (ER+BC). Breast cancer is
the most common tumor diagnosis among women. While the overall 5-year
survival for breast cancer is reaching 90%, the 5-year survival for metastatic
disease is only 22%. Metastasis and endocrine resistance combined can affect
over 50% of patients. One of the proteins and pathways implicated in both
metastasis and endocrine resistance in breast cancer is phosphoserine
aminotransferase 1 (PSAT1) and the serine synthetic pathway (SSP).
From prior reports and preliminary studies within the lab, I hypothesized that
PSAT1 may play a role in metastasis within TNBC and contribute to endocrine
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within ER+BC. The role of PSAT1 in TNBC metastasis was evaluated via
examination of the effects of altered PSAT1 expression on metastatic potential in
TNBC cell lines that were “serine synthesis-independent”. Functional relevance of
PSAT1 on sensitivity to endocrine therapy was tested in matched endocrine
sensitive and endocrine resistant cell lines upon alteration of PSAT1 expression.
Through this work, I found that suppression of PSAT1 significantly inhibited
the in vitro motility and invasiveness of “serine synthesis-independent” TNBC
which was not recapitulated upon suppression of PHGDH, which is the first
enzyme within the SSP. I also found that suppression of PSAT1 reduced the
number of micro-metastases within the lungs in an experimental metastasis model.
In addition, I found that both PSAT1 and PHGDH correlated to poorer progression
free survival in multiple patient cohorts, manipulation of PSAT1 or PHGDH in both
sensitive and resistant ER+BC cell lines altered sensitivity to 4-hydroxytamoxifen
treatment.
This body of work has demonstrated that PSAT1 selectively promotes
metastasis in “serine synthesis-independent” TNBC via a function unrelated to de
novo serine synthesis. It also has shown that both PSAT1 and PHGDH contribute
to tamoxifen resistance in ER+BC and thereby implicating a role for the SSP in this
context. Taken together, this dissertation demonstrates that PSAT1 contributes to
breast cancer progression through promotion of TNBC metastasis and ER+BC
endocrine resistance.
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CHAPTER 1
INTRODUCTION
Breast cancer is the most common malignancy in U.S. women, constituting
30% of all new cancer diagnoses. As the second leading cause of cancer-related
deaths in women [1], it comprised 6.8% of all cancer related mortalities in 2016 [2].
The lifetime risk for a woman developing breast cancer is currently 1 in 8 or about
12% [2]. It is estimated that 268,600 women will be diagnosed with invasive breast
cancer while another 62,930 will be diagnosed with non-invasive breast cancer this
year [1]. At the beginning of 2019 there were in excess of 3.1 million women in the
U.S. with a history of breast cancer [1]. These women though all diagnosed with
breast cancer, do not all have the same disease. Breast cancer has been classified
into 21 different histological subtypes that can be categorized into four main
categories based on their hormone receptor (HR) and human epidermal growth
factor receptor 2 (HER2) status [3]. The four main subtypes are luminal A
(HR+/HER2-), luminal B (HR+/HER2+), triple negative (HR-/HER2-), and HER2
enriched (HR-/HER2+) [3]. These all have different clinical presentations,
oncogenic drivers, treatment options, affected patient populations, and confer
different patient prognoses [3]. This dissertation will focus on two of these
subtypes; triple negative breast cancer (TNBC) and luminal A, which will be
referred to as estrogen receptor positive breast cancer (ER+BC).
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TNBC is characterized by lack of estrogen receptor-α (ERα), progesterone
receptor (PR), and HER2 expression [4]. This molecular subtype accounts for 10%
to 20% of all breast cancer cases [3,5]. It is often considered to be the most
aggressive with the majority of these tumors being high grade at time of diagnosis
and basal-like in their appearance [6]. This aggressiveness is especially alarming
considering the patient populations most commonly diagnosed with this form of
cancer. TNBC is most common among women under 50 years of age, among
women that are African American or Hispanic, and among women that harbor
breast cancer gene 1 (BRAC1) mutations [3,7,8] (Figure 1). The aggressiveness
of TNBC could be due to its heterogeneous nature and the limited treatment
options, given that targeted therapies for breast cancer primarily focus on ERα and
HER2. TNBCs are currently treated with a combination of surgery, chemotherapy
and radiation [3]. Given the propensity of TNBC to be of a higher grade and more
aggressive, there is an increased likelihood of metastasis within this subtype [5].
ER+BC is the most common type of breast cancer observed in the clinic,
accounting for approximately 60% to 75% of all breast cancer diagnoses [9].
These tumors express ERα and their growth and proliferation is driven by estrogen
[10]. ER+ tumors are typically slow-growing and found in older patients, as most
patients with ER+BC are post-menopausal [7]. This subtype also has the best
prognosis, especially at early stages, due to targeted therapies that have been
developed [3] (Figure 1). These therapies target different aspects of estrogen
processing and can be classified into three major categories: aromatase inhibitors,
selective estrogen receptor modulator (SERM), and selective estrogen receptor
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Figure 1: General subtypes of Breast Cancer. This schematic illustrates
patient outcomes according to breast cancer subtypes. Adapted from Dai et al,
2015 [8]. Abbreviations: Estrogen Receptor (ER), Progesterone Receptor (PR),
Human Epidermal Growth Factor Receptor 2 (HER2), Triple Negative Breast
Cancer (TNBC), Estrogen Receptor Positive Breast Cancer (ER+BC).
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degraders (SERD), which also has anti-estrogen activity [10]. The different
categories of endocrine therapy all target estrogen but do so via several different
mechanisms (Figure 2). Aromatase Inhibitors, such as letrozole, prevent the
conversion of androgens to estrogens [11]. Tamoxifen is a SERM and its primary
mechanism of action is through competitive binding against estrogens for the
estrogen receptor resulting in the inhibition of the estrogen driven pro-proliferative
transcription program [12,13]. Fulvestrant (ICI 128,780) is a “pure”-antiestrogen or
SERD [12]. Fulvestrant binds to the estrogen receptor and attenuates estrogen
signaling through blocking estrogen binding and increased ER protein degradation
[12]. Tamoxifen was the first of these targeted therapies and became the standard
first-line therapy in the 1990s [9]. Since its introduction, the mortality rates
associated with breast cancer have decreased significantly [3]. Much of this trend
has been attributed to Tamoxifen, and its later designated replacements, that
target estrogen signaling in ER+ tumors as well as improvements in detection
methods [3].
With these advances in therapies and detection techniques, the current
overall survival rate for female breast cancer has improved and is approaching
90%; however, metastatic disease, where the overall 5-year survival rate is 22%
[2] is still an overwhelming problem. Metastases or advanced recurrent disease
will develop in approximately 30% of patients despite treatment with standard and
advanced therapies [14] and is responsible for 90% of breast cancer-related
deaths [15]. Metastasis occurs when cells disseminate from the primary tumor site
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Figure 2: Endocrine Therapy Mechanisms of Action. This schematic shows
the mechanisms of action for common endocrine therapies. Aromatase
inhibitors inhibit the conversion of testosterone to estrogen. Selective estrogen
receptor modulators (SERMs), represented by Tamoxifen, compete with
estrogen for binding to the estrogen receptor and block estrogen signaling.
Selective estrogen receptor degraders, represented by Fulvestrant, inhibit
estrogen signaling and unlike SERMs also degrade the estrogen receptor.
Adapted from Schmid 2017 [9].
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and populate a distant site. The common distant sites for breast cancer metastases
are bone, liver, lung, brain, and lymph nodes, which vary depending on sub-type
[16]. While metastatic breast cancer can arise from all different breast cancer
subtypes [17], TNBC is considered the most aggressive as it correlates with poorer
overall survival in both early stage and metastatic disease [4]. These metastases
are difficult to treat and unfortunately metastatic disease is often incurable with
therapies primarily directed at prolonging survival while maximizing quality of life
[14]. Several clinical trials with either single agent or combinatorial therapies have
only managed a 3-8 month improvement in overall survival in patients treated with
the prior standard of care (anthracyclines) [14], underscoring a lack of
understanding of a complex process involving numerous proteins and pathways.
The signaling pathways and processes involved in metastasis are highly
regulated and together form the metastatic cascade. This is a series of steps that
a cancer cell must undergo in order to spread from the primary tumor and colonize
in the secondary site (Figure 3). Metastasis in its earliest form begins with the
growth of a tumor within the primary organ. This requires a pro-proliferative protein
signature that promotes genes utilized for growth, proliferation and the necessary
angiogenesis to support this initial tumor growth [18]. Metastasis truly begins when
cells disseminate from the primary tumor [19]. This dissemination requires the cells
to undergo the epithelial to mesenchymal transition (EMT). EMT is a normal
cellular process that is exploited by the cancer cells in order to promote motility,
invasion, and other properties that are needed for the cancer cells to extend
beyond the initial tumor [19].
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Figure 3: The Metastatic Cascade. This schematic depicts the steps involved
in metastasis. First, there must be pro-proliferative signals and angiogenesis to
support the growth of the primary tumor. Cells then undergo EMT which will
allow for motility and invasion resulting in intravasation into the vasculature.
Cells within the vasculature need to survive until they arrive at a secondary site.
The cells then undergo extravasation from the vasculature, revert to their
epithelial form (MET) and colonize a secondary or metastatic site. Adapted from
Daves et al, 2011 [18].
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EMT is initiated by a group of transcription factors that alter transcription of
genes that aid in the invasion and motility of cells. These transcription factors
include Snail, Twist, Slug, and Zeb1 [19]. During EMT, cells change dramatically.
They typically experience downregulation of epithelial-like markers while
simultaneously gaining mesenchymal-like markers which includes loss of cell
polarity and changes in the actin cytoskeleton [20]. In order for a cell to invade into
the vasculature it needs to degrade the extracellular matrix, which is the role of the
matrix metalloproteinases (MMPs). The tumor cells control the expression of
MMPs through several different signaling programs that provide a feed-forward
mechanism for metastasis as MMPs promote the motility and invasion of cancer
cells [21]. The promotion of motility and invasion is classically promoted by actin
cytoskeleton regulation via Rho signaling, integrin signaling, and FAK signaling
cascades [18].
Once in the vasculature, tumor cells must survive in circulation before they
reach a secondary site. According to an established gene signature for metastasis,
the cell is protected in these conditions by the NRF2 stress response and integrin
signaling until the cell can exit circulation through the process of extravasation [18].
To complete this process, cells must invade through the endothelial wall at the
secondary site, which is termed transendothelial migration (TEM) [19]. TEM is only
possible when the endothelial wall has been compromised, a process requiring
MMPs and VEGF [19]. After extravasation, cells must then colonize a secondary
site to form a metastatic tumor. The process of colonization is extremely inefficient
as experimental metastasis models have found that secondary lesions form in only
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0.01% of instances following injection of tumor cells [19]. This is partially due to
the strict requirement for the presence of growth factors at the secondary site that
are necessary for tumor growth [21]. Another determination of whether a cancer
cell will form a metastatic tumor is the successful completion of the mesenchymal
to epithelial transition (MET). There is substantial evidence that suggest that
epithelial cells have a growth advantage in a distant site compared to cells that are
still mesenchymal [20]. While the general metastatic cascade is known and certain
pathways have been identified as contributing to metastasis, there is still a lack of
understanding as to the regulation of the process, especially in regard to unknown
effectors that can be targeted to either prevent or inhibit metastasis.
Another clinical challenge for breast cancer patients is resistance to
therapy. Despite advances in first line treatments, recurrent disease still develops
in some breast cancer patients. This could be due to dormancy of the disseminated
cells that occurs due to lack of adaption in the foreign site or lack of nutrient
availability. Once the cell has adapted to the new environment it can re-enter the
cell cycle and begin to proliferate again. It could also be due to tumor cells
becoming resistant to therapeutic agents, such as antiestrogens for ER+ breast
cancer. While endocrine resistance can ultimately lead to metastatic disease, it
can also present as recurrence after treatment or as progression of the primary
disease during initial therapy [11]. This phenomenon affects numerous patients,
and many will go on to develop resistance to these endocrine therapies. Endocrine
resistance is acquired at different rates depending on staging and time after
diagnosis. Within 5 years, 10-15% of early stage ER+ patients will acquire
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resistance, at 15 years 30% of patients will have recurrent disease despite initial
response to endocrine therapy. Eventually 40-50% of all ER+ patients will
experience relapse, while virtually all metastatic ER+ patients will acquire
resistance in 2-3 years following the start of treatment [22]. The exact mechanisms
by which endocrine resistance occurs and within what patient population are not
fully understood.
However, several mechanisms of endocrine resistance have been
proposed. One of the mechanisms associated with resistance is dependent upon
the expression of ERα. It is suggested that innate resistance is associated with
patients that, while ER+, express lower levels of ERα [22]. In addition, mutations
in ERα can also lead to resistance. Mutations that lead to constitutive activation of
ER without the presence of a ligand would allow the cell to be resistant to both
aromatase inhibitors and antiestrogens [11]. Endocrine resistance has also been
linked to lack of PR expression in ER+ patients [22]. These patients have a poorer
overall survival and often have innate resistance to endocrine therapies [22].
Resistance is also attributed to several other mechanisms that are not
associated with the hormone receptors. Altered Tamoxifen metabolism has been
linked to resistance to Tamoxifen therapy and is reliant upon the patient’s CYP2DG
allele [11]. Differential growth factor signaling is also implicated in endocrine
resistance [11,22]. Most ER+ tumors that also express HER2 are resistant to
endocrine therapy [22]. There is a substantial amount of evidence that supports
crosstalk between ER, PI3K, AKT, and mTOR and that this association is linked to
resistance due to aberrant activation of these pathways which reduce levels of ER
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[11,22]. Studies have shown that patients who responded well to endocrine
therapy had altered expression of the proteome compared to non-responding
patients. These changes in expression have been attributed to epigenetic
regulation of proteins, differences in transcriptional programs, and changes in
expression levels of the ER coregulatory proteins [11,22]. A large majority of these
proteins control the cell cycle or are associated with metabolism [22].
Altered metabolism has been deemed one of the hallmarks of cancer [23].
The differential metabolism associated with cancer cells not only contributes to
initial tumorigenesis but has been established as a factor in therapy resistance and
metastasis [24]. The notion that cancer cells differently utilize the metabolic
processes was first proposed by Dr. Otto Warburg when he noted in the early
1920s that cancer cells preferentially metabolize glucose to lactate even in the
presence of oxygen for oxidative phosphorylation (Warburg effect) [25,26]. These
changes in metabolism allow the cell to use the fuel sources available to them in
nutrient-limiting conditions present in the tumor microenvironment in order to
continue to proliferate and survive [24]. Tumors exploit metabolic pathways,
namely glycolysis, by increasing the expression or activity of transporters and
enzymes responsible for catalyzing the different metabolic reactions in order to
generate building blocks (lipids, amino acid, and nucleotides) needed to sustain
proliferation [24]. In glycolysis, this is achieved via an upregulation of the glucose
transporters to increase glucose uptake coupled with upregulation of glycolytic
enzymes or expression of alternative cancer-specific isoforms (i.e. hexokinase 2)
in order to increase flux through the glycolytic pathway at a rate greater than what
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is required for pyruvate oxidation which leads to increased pyruvate generation
[24]. Additionally, cancer cells also express an alternative isoform of pyruvate
kinase (PKM2) which is less efficient and causes an accumulation of glycolytic
intermediates. This, in turn, increases flux into the glycolytic branching pathways
[24,27,28].
One of those glycolytic branching pathways leads to the de novo synthesis
of serine. There are several different metabolic fates of serine that aid in cell
survival and proliferation including carbon support for production of cysteine,
phospholipid head groups, sphingosine, glycine, glutathione, and purines [28].
Serine can also contribute to redox homeostasis via the reduction of NADPH and
can feed into one-carbon metabolism to support histone, DNA, and RNA
methylation as a result of SAM generation [29]. In addition, serine also serves as
an allosteric activator of PKM, wherein as serine levels increase it promotes PKM2
into its tetrameric form. This form is more active and drives pyruvate generation.
Conversely, when serine levels are low, PKM2 is in a dimeric form and causes the
accumulation of glycolytic intermediates described above [28]. Cells can obtain
serine through either de novo synthesis or uptake via serine transporters. An
individual cell’s pool of serine is largely determined by the tissue of origin which
can determine serine consumption through the expression of the serine
transporters [30]. While most cancer cells can import serine, there seems to be a
preference for de novo serine synthesis, so much so that increased activation of
the serine synthesis pathway (SSP) is now an established component of cancer
metabolism [29,31]. In addition, the SSP is the metabolic pathway that allows for

12

simultaneous utilization of glucose and glutamine as fuel sources to generate
serine and intermediates that feed into the TCA cycle. The SSP is a series of three
reactions that originate from the glycolytic intermediate 3-phophoglycerate and
accounts for approximately 10% of 3-phosphoglycerate that is metabolized [32].
Phosphoglycerate dehydrogenase (PHGDH) is the initiating reaction as it
catalyzes the conversion of 3-phosphoglycerate to 3-phosphopyruvate [33]. The
PHGDH reaction in most tissue types is the rate-limiting step and determines the
overall flux through the pathway. Phosphoserine aminotransferase 1 (PSAT1)
catalyzes the second step in the serine synthesis pathway through conversion of
3-phosphohydroxypyruvate to 3-phosphoserine while interconverting glutamate to
α-ketoglutarate [28]. The last reaction within this pathway is the conversion of 3phosphoserine to serine which is catalyzed by the enzyme phosphoserine
phosphatase (PSPH) [28] (Figure 4). This pathway is utilized differently based on
tissue type in that some tissues do not express enzymes within this pathway,
whereas other tissues rely heavily on de novo serine production.
In the liver, the enzymes within this pathway are expressed at relatively high
levels compared to other tissue types [34] and are subject to regulation by diet and
hormone changes [35]. It has been shown that the expression levels of PHGDH
and PSPH can be directly regulated based on the protein and carbohydrate intake
ratios in the diet [35]. Another difference in normal liver is that this pathway is not
regulated by the activity of PHGDH. Flux through the SSP in the liver is determined
by the activity of PSPH and is driven completely by the cellular need for serine
[35].
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Figure 4: Schematic of the Serine Synthesis Pathway. This schematic
illustrates the three-step serine synthesis pathway and its involvement in
downstream processes.

This pathway is catalyzed by the enzymes

phosphoglycerate dehydrogenase (PHGDH), phosphoserine aminotransferase
1 (PSAT1), and phosphoserine phosphatase (PSPH).
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The SSP in the brain also differs from most other tissue types. In the brain,
there is a reliance upon de novo serine synthesis as serine is known to have low
permeability across the blood-brain barrier [36] and thus the proteins within this
pathway are greatly expressed within this tissue type [34,36]. This is especially
true during development. Patients that harbor mutations that decrease the activity
of any of the serine synthesis enzymes present with neurological disorders [36].
This has been observed for all three enzymes and the extent of the neurological
deficit’s correlates to how much enzyme activity has been maintained. Mutations
in PHGDH have been found in numerous patients and result in severe neurological
issues [36]. Patients have also presented with mutations in PSAT1, which reduced
activity to 15%, and these patients also had severe neurological impairments [37].
As mentioned previously, increased flux through the SSP and increased
expression of the SSP enzymes have been correlated with tumorigeneses in
numerous cancer types [29]. The concept that serine biosynthesis and cancer are
linked is not new. This was first introduced in the 1970s where it was found that
there was increased growth in rat hepatoma cell lines that had higher PHGDH
activity [38]. This was followed by work in the 1980s that found flux through the
SSP was elevated and that this increase correlated with increased tumor growth
[39]. In the years since these original findings, SSP enzymes have been
established as crucial enzymes that are necessary for tumorigenesis in several
different cancer types [29] and have been linked to therapy resistance and
metastasis [28].
Much of this work has focused on the rate-limiting enzyme, PHGDH, as this
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would establish a metabolic requirement for general SSP function. However, there
is evidence to support alternative roles for other enzymes within this pathway.
Therefore, the rest of this dissertation will mainly focus on the relevance of the
enzyme PSAT1. PSAT1 was first molecularly characterized in 2003 [40]. There
are two different isoforms of PSAT1, PSAT1α and PSAT1β, that can be formed via
alternative splicing [40]. Although there are two isoforms, only one, PSAT1β, is
presumed to be physiologically functional as it exhibits a greater level of
expression compared to the α isoform [40]. The expression of PSAT1 depends on
tissue type and cell cycle phase. PSAT1 is highly expressed in the brain, liver,
kidney and pancreas and reaches maximum expression levels during S-phase
[40]. As mentioned earlier, PSAT1 can also convert glutamate to α-ketoglutarate.
This gives PSAT1 a role in embryonic stem cell differentiation via control of αketoglutarate levels [41] as it is estimated that PSAT1 accounts for 50% of the
anaplerotic flux into the TCA cycle [27]. There has also been a substantial amount
of evidence to support a role for PSAT1 specifically in cancer.
PSAT1 has been shown to be more active in neoplastic and proliferating
tissues when compared to normal tissues [42]. This is due to lack of PSAT1
expression in many normal tissue types including lung, colorectal, ovarian and
mammary tissues [34]. However, in tumors originating from these tissues
expression of PSAT1 is greatly increased [43]. This upregulation of PSAT1 in these
neoplastic cells has been linked to several different mechanisms, including
epigenetic, miRNA, and transcriptional control.
Epigenetic regulation of PSAT1 has been shown to be a mechanism for

16

increased serine synthesis. One epigenetic mechanism is reliant upon the
interaction between menin and MLL1 which, when activated, maintains expression
of the SSP enzymes in order to support proliferation, cell viability and tumor growth
in Ewing Sarcoma [44]. Another epigenetic mechanism involves methylation at
H3K9. In this context, euchromatic histone lysine methlytransferase 2 (G9A) adds
an activating monomethylating mark, H3K9me1, in order to drive transcription [45].
Conversely, KDM4C removes the repressive modification of H3K9me3 which
allows the transcription of this SSP enzyme [46]. Transcription following this
epigenetic activation also requires activating transcription factor 4 (ATF4) [46].
This transcription factor has been shown to regulate PSAT1 in several
different cancer types. In lung cancer, ATF4, under control of NRF2, regulates SSP
enzyme expression in order to support glutathione and nucleotide production [47].
Also in lung cancer, ATF4 tethers MDM2 to the chromatin in order to drive
activation of serine synthesis in order to support amino acid metabolism and redox
homeostasis [48]. Lastly, ATF4 has been shown to regulate expression of PSAT1
in breast cancer to promote cell cycle progression [49].
There are also proteins other than ATF4 that have been implicated in
regulating the serine synthesis pathway. The entire pathway is regulated by p73
via glutaminase 2 (GLS-2) in lung cancer as a result of a need for converting
glutamine into glutamate [50]. In Ewing Sarcoma, EWS-FLI1 drives SSP
expression while increasing the uptake of glutamine in order to maintain redox
homeostasis [51]. Along the same idea, SSP enzyme expression has been shown
to be upregulated in response to different stress signals found in the tumor
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microenvironment. In liver cancer, glucose and glutamine deprivation resulted in a
C-MYC-dependent increase in the enzymes of the SSP to support glutathione
production, cell cycle progression, and nucleic acid synthesis [52]. Arginine
deprivation was also shown to cause an upregulation in the SSP enzymes [53]. It
has also been shown that serine deprivation causes an increase in the expression
of the SSP enzymes to support cell survival by providing serine to maintain
proliferation and mammalian target of rapamycin complex 1 (mTORC1) activity
[54]. The SSP enzymes, including PSAT1, have also been shown to be induced
by hypoxic conditions found in the tumor microenvironment [55].
PSAT1 can also be regulated independently from the other enzymes in
serine synthesis pathway. PSAT1 has been shown to be a direct target of miR340, miR-365, and miR-424 [56-58]. This regulation occurs in both esophageal
(miR-340 and miR-365) and colorectal cancer (miR-424). In every instance, the
miRNA was acting as a tumor suppressor and loss of the miRNA resulted in an
increase in PSAT1 expression and a subsequent increase in the tumorigenic
properties of those cancer types [56-58].
Besides miRNA regulation, there are several other mechanisms implicated
in the specific regulation of PSAT. In lung cancer, PSAT1 expression is controlled
by the deactivation of NF1. The subsequent activation of FAK1 results in a
glutamate dependence that is reliant upon PSAT1 [59]. In breast cancer two
different means of regulation have been suggested for PSAT1. One proposed
mechanism is through the transcription factors TAZ/YAP [60]. In this scenario
TAZ/YAP induce PSAT1 expression to mediate a growth dependence on
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exogenous glutamine [60] and this is primarily observed in high grade TNBCs
[60,61]. The other proposed mechanism in breast cancer is regulation by the
PI3K/Akt/mTOR pathway [62]. Control of PSAT1 in this pathway was achieved via
a reduction of mRNA and protein levels of PSAT1 following mTOR inhibition and
MyrAkt induction was able to attenuate this reduction in expression [62]. It was
also determined that the regulation of PSAT1 by the PI3K/Akt/mTOR pathway was
independent of proliferation [62]. Induction of expression of PSAT1 by mTORC1
was also observed in pancreatic cancer, but in that context, it seemed to be a
means of SSP regulation and not PSAT1 specifically [63]. These various
mechanisms utilized for the regulation of PSAT1 demonstrate a need for the
expression of this protein in cancer cells and suggests that PSAT1 plays a crucial
role in malignant disease.
As noted, PSAT1 has been demonstrated to have increased expression in
several types of cancer. This upregulated expression appears to be directly related
to survival in most of these cancer types. Its expression has been correlated with
increased proliferation, resistance to therapy, metastasis, and poorer patient
outcomes. The following section will focus on what role, if known, PSAT1 plays in
various cancer types and if these roles are related to the SSP or an independent
function of PSAT1.
PSAT1 in Thyroid Cancer
In thyroid cancer, the serine synthesis pathway is activated and requires
PSAT1 activity. It was found that the expression levels of the SSP enzymes could
determine the subtype of thyroid cancer, as the SSP enzymes had higher

19

expression in the poorly differentiated carcinoma (PDC) and papillary thyroid
carcinoma (PTC). Yet, they had very low expression in the medullary carcinoma
(MC) subtype [64]. This group also found that a BRAF mutation (V600E)
associated with PSAT1 expression. Patients with this BRAF mutation had higher
expression of the SSP enzymes compared to patients with wild-type BRAF [64].
PSAT1 in Nasopharyngeal Carcinoma
In nasopharyngeal carcinoma, PSAT1 was identified as a potential
biomarker for prognosis [65]. In this cancer type, high PSAT1 expression
associated with an aggressive clinical course and advanced tumor stage. In
addition, it correlated with reduced disease-specific survival, distant-metastaticfree survival, local-recurrence-free survival, overall survival, and was an overall
indicator of poorer patient prognosis [65].
PSAT1 in Melanoma
The effects of PSAT1 in melanoma are directly related to its function
regarding serine biosynthesis. Melanoma has one of the highest frequencies of
PHGDH amplifications compared to other cancer types [66]. This amplification of
PHGDH, along with increased expression of the other SSP enzymes, results in
increased flux through the serine biosynthetic pathway [67]. Cells that harbor these
PHGDH amplifications are sensitive to PHGDH, or other SSP enzyme,
suppression where silencing leads to a reduction in cell proliferation [67]. These
SSP enzymes, including PSAT1, have also been identified as necessary for the
observed resistance to BRAF inhibitors in this cancer type [68].
PSAT1 in Pancreatic Cancer
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The role of PSAT1 in pancreatic cancer is also related to its function in the
serine synthesis pathway. The SSP enzymes in pancreatic cancer can be induced
by mTOR [63]. This overexpression is required for further down-stream one-carbon
metabolism that supplies the s-adenosylmethionine levels in order to meet the
methylation needs of the cell [63]. The overexpression of PSAT1 is also required
for tumorigenesis of pancreatic cancer, especially under the conditions of liver
kinase B1 (LKB1) loss. Upon loss of LKB1, PSAT1 is required for proliferation,
colony formation, and subcutaneous tumor growth [63]. SSP enzymes have also
been identified as necessary components of BRAF inhibitor resistance [68]. In
resistant cell types, the BRAF inhibitor vemurafenib induced the expression of the
SSP enzymes and resulted in an increase in cell proliferation [68].
PSAT1 in Multiple Myeloma
The expression of PSAT1, and other serine synthesis enzymes, in multiple
myeloma has been directly associated with resistance to therapeutic treatment
[69]. It was observed that all SSP enzymes had higher expression in cell types that
were determined to be resistant to bortezomib [69]. This correlation was so
significant that it was determined that SSP enzyme expression could potentially be
used as a biomarker to identify patients that would be resistant to this therapeutic
option [69].
PSAT1 in Hepatocellular Carcinoma
The role of PSAT1 in normal liver differs from other tissues and this also
extends to tumors originating from this tissue type. In hepatocellular carcinoma,
PSPH, the rate-limiting enzyme in the liver, is significantly upregulated compared
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to normal liver expression while PHGDH and PSAT1 are downregulated [70]. It is
suggested that these expressions patterns are due to a developed reliance on
glutamine within the tumor in order to fuel the TCA cycle [70].
PSAT1 in Glioblastoma
With the dependence in the brain on de novo serine synthesis, these
proteins are normally expressed at higher levels than other tissues [34]. In
glioblastoma, there is a reduction in the expression of PSAT1 in tumors compared
to normal tissue and this reduction in expression is exacerbated in higher grade
tumors compared to lower grade tumors [71]. It was also determined that certain
therapies, i.e. Regorafenib, require high PSAT1 expression in order to suppress
tumor growth in glioblastoma multiforme [71].
PSAT1 in Ewing Sarcoma
In Ewing sarcoma, the entire serine synthesis pathway is highly active, and
these enzymes (PHGDH, PSAT1, and PSPH) are essential for proliferation,
viability, and tumor growth [44]. This pathway has also been associated with
regulation of redox homeostasis and protecting these tumors against DNA damage
and apoptosis [51]. The expression of the SSP enzymes are also an indicator of
prognosis within this cancer type. Patients with higher expression are classified as
a high-risk group with poorer overall survival [51].
PSAT1 in Esophageal Squamous Cell Carcinoma
PSAT1 expression is elevated in esophageal squamous cell carcinoma
compared to normal tissue [72]. Characteristically, elevated PSAT1 expression
contributes to proliferation, epithelial to mesenchymal transition, invasion, and
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progression [57,58,72]. Higher expression of PSAT1 also enhanced tumor
formation in vivo [72]. Functionally, it is suggested that PSAT1 is contributing to
these tumorigenic processes via a promotion of GSK3β/snail activity [72].
Clinically, increased expression of PSAT1 has been correlated with stage of
disease, lymph node metastasis, distant metastasis, and overall poorer patient
prognosis [72].
PSAT1 in Colon Cancer
PSAT1 is highly expressed in colon tumor tissue compared to normal colon
[73,74] and has even been identified as the most upregulated gene in colorectal
carcinoma [75]. Increased PSAT1 expression in colon cancer has been shown to
have an integral role in tumor growth both in vitro and in vivo as well as evasion of
apoptosis [56]. Clinically, higher levels of PSAT1 expression has been associated
with chemo-resistance [73,75]. Increased PSAT1 expression correlates with a
reduced sensitivity to oxaliplatin [73] as well as resistance to irinotecan, 5fluorouracil, and leucovorin therapy and a resulting decrease in patient survival
time [75]. This finding has led to the suggestion that PSAT1 be used as a biomarker
for resistant colorectal carcinoma [75]. Mechanistically, it seems that PSAT1 is
contributing to an increased growth rate and chemo-resistance via a canonical
function in serine-synthesis and downstream one-carbon metabolism [76].
PSAT1 in Ovarian Cancer
In ovarian cancer, PSAT1 expression is increased in tumor tissue compared
to adjacent normal tissue [77-79]. This overexpression can be used as a biomarker
to sort into different molecular categories as PSAT1 was observed to be strongly
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expressed in the ovarian clear cell carcinoma subtype [78]. It has also been found
that PSAT1 expression levels correlate to clinical stage and tissue differentiation
[79]. Elevated PSAT1 expression contributes to disease occurrence, development,
and prognosis [79] via a promotion of GSK3β phosphorylation, angiogenesis, and
enhanced expression of HIF-1α, VEGF, and β-catenin [77]. In addition, elevated
PSAT1 expression in ovarian cancer has been linked to resistance to cisplatin
treatment [77].
PSAT1 in Lung Cancer
In lung cancer there is evidence for both SSP and independent roles of
PSAT1. The function of PSAT1 in lung cancer that is related to serine biosynthesis
is driven by a need for flux through the pathway in order to generate serine. This
supports cell proliferation and mTORC1 activity during times of serine deprivation
[54]. This also occurs as a response to oxidative stress [50] as a means to regulate
redox homeostasis during these conditions [48]. Reliance upon the SSP has also
been defined as a specific molecular subtype in lung adenocarcinoma. The
enzymes in the SSP are upregulated in this pathway in order to maintain flux
through the serine pathway and correlates with significantly poorer patient
prognosis [80]. In addition, PSAT1 was found to be significantly upregulated in
non-small cell lung cancer [81]. This increase contributed to cell cycle progression,
cell proliferation, tumorigenesis, and was involved in the regulation of the Rb-E2F
pathway activity by inhibition of cyclin D1 degradation [81]. This suggests that
PSAT1 may have a function outside of its enzymatic activity in contributing to
generation of serine. In addition, clinically overexpressed PSAT1 conferred a
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poorer clinical outcome for patients [81] PSAT1 was also identified as mediating a
glutamine dependence in a subset of Kras driven lung adenocarcinomas that
harbor a loss of function mutation in NF1 via a FAK1-dependent mechanism [59].
PSAT1 in Breast Cancer
A connection between PSAT1 expression and breast cancer was first
described in 2005 by Martens et al. They found that the extent of methylation on
the PSAT1 promoter, and thus PSAT1 mRNA expression, was indicative of a
response to tamoxifen therapy in ER+BC with recurrent disease [82]. Since then,
there has been an increase in the investigation into the role of the serine synthesis
pathway and PSAT1 in the development, progression, and treatment of breast
cancer. Most of this work has looked at PSAT1 in the context of its canonical
function within the serine synthesis pathway.
It has been determined that serine synthesis pathway enzyme expression
levels in breast cancer could predict patient survival [83]. The enzymes in the SSP
were upregulated in a metastatic variant of TNBC breast cancer and that this
increase was correlated with decreased relapse-free and overall survival of
patients with TNBC [84]. It was also noted in these studies that increased serine
biosynthesis promoted bone metastasis via the stimulatory effect of serine on
osteoclastogenesis [84] and that PSAT1 expression specifically was required for
this development [85]. Certain breast cancers exhibit a dependence on flux
through the serine synthesis pathway, driven by a dependence on PHGDH as the
rate-limiting enzyme. In these subsets, SSP enzyme expression is required for
tumorigenesis and correlates with aggressiveness of disease [86-88]. This
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requirement for flux through the SSP, also termed serine synthesis-dependence,
makes these cells sensitive to manipulation in SSP enzyme expression wherein
either genetic reduction or pharmaceutical inhibition causes a significant
proliferative defect in these cell types [86,87,89]. As was mentioned earlier,
hypoxia can induce expression of the SSP enzymes. This hypoxic induction of the
SSP enzymes allows for the maintenance of redox homeostasis as serine
synthesis reactions generate NADPH [90]. This causes an enrichment in breast
cancer stem cells and indicates a role for this pathway in the evasion of cell death
from chemotherapy treatment and in the formation of secondary tumor sites
[55,91]. The increased expression of the SSP enzymes are not restricted to tumor
cells. It has also been showed that there is an increase in SSP enzymes in stromal
tissue that correlates with an increase in histological grade of breast phyllode
tumors [92]. In addition, there is evidence to support that depending on the
origination of the disease, i.e. ductal or lobular, expression of the SSP enzymes
will be higher in either the tumor cells (invasive lobular carcinoma) or stromal tissue
(invasive ductal carcinoma) [93].
Outside of the serine synthesis pathway in general, there has been
investigation into the role of PSAT1 in breast cancer. PSAT1 was shown to have
higher expression in estrogen receptor negative cancers compared to estrogen
receptor positive cancers due to a loss of promoter methylation [94]. In addition to
ER status, PSAT1 promoter methylation (i.e. lack of PSAT1 expression) correlated
with low-grade, low-proliferation, lymph node positive BC in women who were postmenopausal and Caucasian [95]. Low promoter methylation of PSAT1 (i.e. high
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PSAT1 expression) was associated with higher tumor grade, pN stage, and poorer
disease-free survival in patients [96]. As mentioned earlier, PSAT1 mRNA levels
were able to be a predictor of response to tamoxifen treatment [82]. That work was
further expounded upon and demonstrated that protein levels of PSAT1 were also
associated with poorer patient outcome upon tamoxifen treatment [97]. Further,
high PSAT1 expression has been correlated to poorer overall survival, recurrence
free survival, and identified as part of a gene signature inclusive of all breast cancer
subtypes [98].
While it is evident that there is an increase in the expression of PSAT1 in
several cancer types and that increased PSAT1 generally associates with clinical
outcomes, I will be focusing the rest of this dissertation on the role(s) of PSAT1 in
breast cancer. It is known that PSAT1 is increased in breast cancers and that this
increase correlates with poorer survival for patients; however, the requirement of
PSAT1 in different subtypes of breast cancer is still poorly understood in the
progression of this disease. While there is a clear indication that there is a role for
PSAT1’s function within the serine synthesis pathway in breast cancers that are
serine synthesis-dependent, this only accounts for a limited subset of breast
cancers. In cancers that are classified as independent of serine synthesis, yet still
express elevated levels of PSAT1, it is unclear what function or role increased
PSAT1 provides the tumor in this context. The majority of this doctoral work has
been completed in the context of TNBC as the expression of PSAT1 is greater in
this molecular subtype even in those TNBCs designated as serine synthesis
independent. However, PSAT1 has also been reported to be expressed in ER+BC,
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especially in tumors that are resistant to endocrine therapy. To date, there is no
indication of whether this therapy induced increase in expression promotes either
elevated flux through the serine pathway or a non-canonical function of PSAT1
that contributes to acquired resistance.
These gaps in knowledge are the basis for this dissertation. The role of
PSAT1 in a serine synthesis-independent system will be examined in TNBC. The
rationale for investigation in this molecular subtype is that while a large portion of
TNBCs (70%) upregulate the serine biosynthetic enzymes, only 6% of that 70%
are due to genetic amplification of PHGDH [87]. These statistics suggest that there
is a large subset that may upregulate PSAT1 independently of other SSP enzymes
and thus the function for this increase is unknown. Due to the metastatic nature of
TNBCs, the variable independent increases observed in PSAT1, PSAT1’s
correlation with higher grade TNBCs, and the association between higher grade
tumors and metastasis, we speculate that PSAT1 may be involved in the
metastatic potential of TNBC (Aim 1) and this function of PSAT1 is unrelated to its
function in serine biosynthesis (Aim 3).
The other aim (Aim 2) of this dissertation is to further investigate a finding
by Martens et al. High expression of PSAT1 was demonstrated as the strongest
negative correlation with response to endocrine therapies in a study on patients
with recurrent ER+ breast cancer [82]. In a follow-up study these results were
confirmed at the protein level and in a second patient cohort [97]. This second
study suggests that the contribution of PSAT1 to resistance may rely on flux
through the serine synthesis pathway as increases in PHGDH were also observed.
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It is my goal to examine the effects of altered PSAT1 expression on the sensitivity
to endocrine therapy in both endocrine sensitive and resistant ER+BC. In addition,
we will examine whether these suggested functions of PSAT1 are the result of its
involvement in the serine biosynthetic pathway.
The elevated expression of PSAT1 in breast cancer compared to normal
mammary tissue, combined with previously published data and our own results
suggests that PSAT1 contributes to breast cancer progression by promoting TNBC
metastasis in a serine-independent context and endocrine resistance in ER+BC
possibly through a requirement for serine synthesis. I have devised three aims to
evaluate this hypothesis.
1. Determine the effect of PSAT1 suppression in breast cancer
metastasis in vitro and in vivo. This aim will be evaluated in a specific
subset of TNBC that is “serine synthesis-independent” and will implement
several in vitro assays of metastatic characteristics.
2. Determine the effect of PSAT1 expression on endocrine resistance
within ER+BC. This aim will be evaluated in both ER+ endocrine sensitive
and endocrine resistant cell lines and determine if suppression of PSAT1
affects sensitivity to endocrine therapies.
3. Determine if there is a requirement for serine synthesis and thus
PSAT1 in breast cancer progression. The requirement for serine
synthesis will be evaluated in our TNBC model system and employ both the
suppression of PSAT1 as well as the suppression of the rate-limiting
enzyme PHGDH.
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CHAPTER 2
SELECTIVE LOSS OF PHOSPHOSERINE AMINOTRANSFERASE 1 (PSAT1)
SUPPRESSES TRIPLE NEGATIVE BREAST CANCER METASTASIS
Introduction
Breast cancer is the most prevalent cancer diagnosis and the second
leading cause of cancer-related deaths among women. Metastatic disease is
responsible for over 90% of breast cancer related mortalities [15], which
culminates in an overall survival rate of 22% for metastatic patients [2]. Metastasis
or advanced recurrent disease affects approximately 30% of patients and is
clinically challenging as therapies are often directed at prolonging survival without
compromising quality of life [14]. Metastasis can arise from all breast cancer
subtypes [17] but triple negative breast cancer (TNBC) is considered the most
aggressive as it correlates with poorer overall survival in both early stage and
metastatic disease [4]. Separate from hormone receptor positive breast cancers,
TNBC is characterized by the lack of estrogen receptor-α (ERα), progesterone
receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression
[4].
Despite the inherent heterogeneity of TNBC tumors, 70% of TNBCs
upregulate the expression of enzymes within the serine synthesis pathway (SSP)
[87]. The SSP is a glycolytic shunt that is responsible for converting 330

phosphoglycerate into serine through a series of three reactions. The first reaction,
and rate-limiting step, is catalyzed by phosphoglycerate dehydrogenase (PHGDH)
and converts 3-phosphoglycerate into 3-phosphohydroxypyruvate. The second
enzyme, phosphoserine aminotransferase (PSAT1), couples the conversion of
glutamate

to

α-ketoglutarate

with

the

production

of

3-phosphoserine.

Phosphoserine phosphatase (PSPH) then dephosphorylates 3-phosphoserine into
serine. Most of the previous work involving the SSP and TNBC has focused on a
role for PHGDH. Select primary TNBCs and TNBC cell lines have been previously
designated as “serine-dependent” or reliant on the cellular production of serine.
These cells harbor genetic amplifications of PHGDH or have extremely high
PHGDH expression, within which PHGDH silencing causes a significant decrease
in proliferation due to loss of alpha-ketoglutarate production through PSAT1 [87].
However, these gene amplifications of PHGDH only account for 6% of primary
tumors and 18% of breast cancer cell lines [87]. “Serine synthesis-independent”
TNBC cell lines do not harbor genetic amplifications of PHGDH and loss of SSP
enzymes yields no anti-proliferative effect in the presence of exogenous serine.
Yet, many of these cell types demonstrate elevated expression of the SSP
enzymes compared to normal breast tissue, particularly PSAT1, suggesting that
these enzymes may have additional functions in TNBC progression [55,87].
While PSAT1 is not expressed in normal mammary tissue [34], it is elevated
in several breast cancer subtypes as well as in several other aggressive
malignancies including colon cancer, nasopharyngeal carcinoma, human
esophageal squamous cell carcinoma, and non-small cell lung cancer
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[49,55,65,72,73,81]. Control of PSAT1 expression is driven by several oncogenic
pathways and is differently regulated throughout cell-cycle progression
[42,44,47,49,50,52,60]. Increased PSAT1 expression has been correlated with
multiple tumorigenic characteristics, including metastasis and chemoresistance,
and is correlated with poorer patient prognosis [49,72,73,81,84].
Based on previous reports detailing the requirement for SSP enzymes in
“serine synthesis-dependent” TNBC proliferation coupled with PSAT1’s elevated
expression in “serine synthesis-independent” TNBC cells, we examined PSAT1’s
potential contribution to other TNBC features, particularly in metastatic potential.
In this report, we demonstrate that PSAT1 expression increases with TNBC grade
and that selective suppression of PSAT1 inhibits metastatic characteristics both in
vitro and in vivo without affecting proliferation. Importantly, loss of PHGDH in
“serine synthesis-independent” cells did not phenocopy PSAT1 silencing,
suggesting that these effects are specific to PSAT1 in these cell types. Together,
these data indicate that PSAT1 plays a role in metastatic potential in TNBC.
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Methods and Materials
Immunohistochemistry
PSAT1 expression was determined in a panel of commercially available
tissue microarrays (TMA) that contained de-identified TNBC tumor core sections
with provided clinical characteristics, such as grade and histological status of the
estrogen and progesterone receptors and HER2 (US Biomax, BR487, BR243,
BR1503, and BR1504). TMAs were dewaxed and rehydrated using a series of
xylene and ethanol washes. Tissues were then blocked with 5% goat serum and
incubated with 1:100 dilution of anti-PSAT1 antibody (ProteinTech) for 16 hours at
4°. Sections were subsequently incubated with 1:1000-fold dilution of HRPconjugated anti-rabbit antibody. PSAT1 was detected using DAB stain (Vector
Laboratories), counterstained with hematoxylin, and image was digitally captured
using AperioScope digital slide scanner.
Analysis of PSAT1 staining in TNBC sections (ER-, PR-, and HER2staining as defined by the provided histological reports with each TMA) was
performed using Aperio ImageScope software with the positive pixel count
algorithm. Areas of analysis excluded stromal tissue in the tumor samples and was
defined to ductal epithelial in the normal breast tissue sections. Comparison of
relative PSAT1 levels between normal, grade 1, grade 2, and grade3 TNBC tissues
was determined by dividing the positive pixel count by total pixels (sum of positive
and negative) as determined by the software.
Cell Culture
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The MDA-MB-231 and HCC1806 TNBC cell lines were obtained from
ATCC. MDA-MB-231 cells were cultured in IMEM supplemented with 5% FBS and
gentamicin and

HCC1806

cells

were cultured

in

RPMI-1640

medium

supplemented with 10% FBS and gentamicin. HEK 293T cells were also obtained
from ATCC and cultured in DMEM supplemented with 10% FBS and gentamicin.
All cells were incubated at 37° in 5% CO2.
Plasmid Generation
The PSAT1 and TIMP2 genes were isolated via the utilization of primers
targeting the 3’ and 5’ ends of the mature RNA encoding for either PSAT1 or
TIMP2. These primers were adapted to include the restriction enzymes ECOR1
and BAMH1. Polymerase chain reactions were performed to amplify the region
and the products were then separated via gel electrophoresis. The corresponding
bands were excised from the gel and purified. They were then ligated into either a
FLAG-tagged vector (PSAT1) or a GFP-tagged vector (TIMP2), transformed into
bacterial strains, and plated on LB agar with ampicillin. A single bacterial colony
was then cultured in LB broth and ampicillin for 24 hours and plasmids were
isolated from the culture via the Qiagen Miniprep kits and confirmed by
sequencing.
Transfections
PSAT1 siRNA and scrambled negative control siRNA were purchased from
Ambion. PHGDH siRNA and non-targeting control pool siRNA were purchased
from Dharmacon. PSAT1 shRNA, PHGDH shRNA, and Control shRNA were
purchased from Sigma. The FLAG-PSAT1 and GFP-TIMP2 were generated as
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described above. For overexpression, FLAG-PSAT1, GFP-TIMP2, and the empty
vectors were transfected into HEK 293 cells using the Polyplus jetPRIME reagent.
For transient suppression, siRNAs were transfected into either MDA-MB-231 or
HCC1806 cells using RNAiMax Lipofectamine or Polyplus INTERFERin systems
according to manufacturer’s protocol. For stable suppression cell line generation,
shRNAs were transfected into cells using the Polyplus jetPRIME reagent according
to manufacturer’s protocol and clonal selection for gene silencing was performed
using puromycin. The sequences for all siRNA and shRNA species are as follows:
PSAT1 RNAi: 5’-CCCUAAACUUGGGAGUUAUtt-3’, negative control RNAi:
Silencer Select Negative Control No. 2 cat#4390846, PHGDH RNAi: 5’CGACAGGUUGCUGAAUGA-3’,

non-targeting

UGGUUUACAUGUCGACUAA-3’,

pool

RNAis:

5’-

5’-UGGUUUACAUGUUGUGUA-3’,

5’-

UGGUUUACAUGUUUUCUGA-3’, 5’-UGGUUUACAUGUUUUCCUA-3’, PSAT1
shRNA:

5’-

CCGGGCACTCAGTGTTGTTAGAGATCTCGAGATCTCTAACAACACTGAGTG
CTTTTTG-3’,

PHGDH

shRNA:

5’-

CCGGCTTCGATGAAGGACGGCAAATCTCGAGATTTGCCGTCCTTCATCGAA
GTTTTTG-3’,

Control

shRNA:

5’-

CCGGCAACAAGATGAAGAGCACCAACTCGAGTTGGTGCTCTTCATCTTGTT
GTTTTT-3’.
Immunoblot Assays
Whole-cell lysates were prepared in IP Lysis Buffer (Pierce) containing
protease and phosphatase inhibitors. Proteins were separated on 10% SDS-
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polyacrylamide gels and transferred to PVDF. Membranes were blocked with 5%
non-fat dry milk in TBS-T and subsequently probed with 1:1000-fold dilution of antiPSAT1 (Proteintech, 10501-1-AP) or anti-PHGDH (Sigma HPA021241) antibodies
for 16 hours at 4°. Washed membranes were then incubated with 1:5000 dilution
of HRP-conjugated anti-rabbit or anti-mouse secondary antibodies. Protein
detection was done by exposure to ECL Prime chemiluminescent reagent (GE
Healthcare). Protein loading was assessed using anti-β-actin antibody (Sigma,
A2228).
Cell Proliferation
For shRNA silencing, MDA-MB-231 (50,000) cells with or without stable
knock-down of PSAT1 or PHGHD were seeded in triplicate in a 12-well (Corning)
plate. Cell proliferation was assessed by counting of trypan blue excluded cells 24
and 48-hours post-seeding. For siRNA suppression, MDA-MB-231 (50,000) or
HCC1806 (30,000) were seeded in 12-well or 24-well (Corning) plate respectively,
24-hours post-transfection. Cells were then counted via trypan blue exclusion 24
or 48-hours post-seeding.
Wound Healing Assay
MDA-MB-231 or HCC1806 cells were seeded at 200,000 cells per well in a
12-well (Corning) plate. Cells were either seeded directly (stable shRNA
suppression) or 24-hours post siRNA transfection. Scratch in the confluent
monolayer was generated with a sterile 200μL pipette tip. Images were taken at
0HR and 24HR time intervals and % wound healing was quantified using ImageJ.
Migration and Invasion Assays
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For migration assays, MDA-MB-231 and HCC1806 cells were serum
starved for 24 hours and then plated (25,000 and 50,000 respectively) into Boyden
chambers in serum-free medium. Serum-containing medium was placed in each
well to serve as the chemoattractant. At 24 hours, inserts were fixed with 100%
methanol for 10 minutes and non-migrated cell were removed with a cotton swab.
The inserts were then washed with PBS and stained with crystal violet. Images
were captured via an EVOS microscope and multiple 4X fields were analyzed with
ImageJ.
For invasion assays, MDA-MB-231 cells were serum starved for a period of
24 hours and then plated (50,000) into Corning Biocoat Matrigel Invasion
Chambers (Corning) following rehydration according to manufacturer’s protocol.
The cells were allowed to invade for 24 hours at which point the inserts were fixed
with 100% methanol for 10 minutes and non-invasive cells and remaining matrigel
layer were removed via cotton swab. The inserts were then washed with PBS and
stained with crystal violet. Images were captured via an EVOS microscope and
multiple 4X fields were analyzed with ImageJ.
Quantitative-Real Time Polymerase-Chain Reaction
MDA-MB-231 or HCC1806 cells were collected and total RNA was isolated
using the RNeasy Mini Kit (Qiagen). One milligram of RNA was converted to cDNA
using the High-Capacity RNA-to-cDNA kit (appliedbiosystems) according to the
manufacture’s protocol. Samples were then analyzed for qPCR via the TaqMan
Fast Advanced (appliedbiosystems) system with human probes for PSAT1
(Hs00795278_mH), PHGDH (Hs00198333_m1), and ACTB (Hs01060665_g1).
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Anchorage-Independent Growth
A bottom layer of 0.6% noble agar in complete medium was prepared in sixcentimeter dishes. MDA-MB-231 cells were seeded at 50,000 cells per dish in a
0.3% agar solution. Cell colonies were refreshed with 0.25% agar/medium solution
every 3-5 days during the 21-day assay. Images were captured via a Nikon digital
camera (DXM1200F) attached to a Nikon (SMZ1500) microscope.
Actin Cytoskeleton Staining
MDA-MB-231 (30,000) or HCC1806 (60,000) cells were plated in Lab-Tek
II Chamber slides (154526) either directly or following transfection with siRNA
species. Forty-eight hours after plating, cells were fixed with 3.7% formaldehyde
solution. The cells were then permeabilized with 0.1% Triton X-100 in PBS before
staining with phalloidin (Thermo Fisher) and DAPI (Thermo Fisher) following
manufacturer’s protocol. Cellular staining was visualized using an Olympus FV3000 confocal microscope equipped with Flouview software (Olympus America
Inc.) under 40X magnification.
Animal Model for Experimental Metastasis
The in vivo study was approved by the University of Louisville’s Institutional
Animal Care and Use Committee. The experimental in vivo metastasis model was
performed as previously established for MDA-MB-231 cells [99]. Briefly, MDA-MB231 cells with or without PSAT1 silencing were collected, washed, and
resuspended in PBS at a concentration of 1 x 106/mL. One hundred microliters of
cell suspension were intravenously injected into the tail vein of athymic nude mice
(Charles River). Lung tissue was resected 8 weeks post-injection, formalin fixed,
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and embedded in paraffin. FFPE lung tissue was sectioned and stained with
hematoxylin and eosin to detect MDA-MB-231 lung lesions. Images were captured
using AperioScope digital slide scanner and micro-metastatic foci were counted
from three separate image fields (under 4X magnification) across individual tissue
sections from each animal.
Co-Immunoprecipitation
HEK 293T cells were transfected with FLAG-PSAT1 and GFP-TIMP2.
Forty-eight hours post transfection, cell pellets were collected and whole-cell
lysates were prepared in IP Lysis Buffer (Pierce) containing protease and
phosphatase inhibitors. Anti-FLAG M2 magnetic beads (Sigma) were prepared
according to manufactures instructions prior to overnight incubation with 1mg of
protein lysate. Proteins not bound to the beads were removed by washing prior to
elution. Remaining proteins were separated on 10% SDS-polyacrylamide gels and
transferred to PVDF. Membranes were blocked with 5% non-fat dry milk in TBS-T
and subsequently probed with 1:1000-fold dilution of anti-FLAG (DYKDDDDK)
(Cell Signaling, 23685), anti-PSAT1 (Proteintech 10501-1-AP), or anti-GFP
(Sigma G1546) antibodies for 16 hours at 4°. Washed membranes were then
incubated with 1:5000 dilution of HRP-conjugated anti-rabbit or anti-mouse
secondary antibodies. Protein detection was done by exposure to ECL Prime
chemiluminescent reagent (GE Healthcare).
Statistical Analysis
Statistical analysis of all studies was performed with Graph Pad Prism
software using either analysis of variance or unpaired t test. p values for all results

39

are indicated in their respective figure legends.
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Results
PSAT1 expression increases with TNBC grade
In support of the clinical relevance of the serine synthetic pathway in TNBC,
we performed immunohistochemistry analysis of breast tissue samples from
normal tissue, or at varying grades of TNBC. Similar to previous reports [34], we
found that normal breast tissues express low levels of PSAT1 compared to TNBC
(Figure 5A). Quantitation of PSAT1 staining revealed a trend towards elevated
levels in grade 1 tumor tissue that is significantly increased in higher grades within
these TNBC tissues (Figure 5B). These results demonstrate that PSAT1 is
expressed in breast tumor tissue, suggesting that PSAT1 has a potential role in
the progression of TNBC.
Suppression of PSAT1 inhibits migration and invasion of select TNBC cell
types without affecting cell proliferation
Prior studies have established the SSP as a crucial pathway in cancer
progression, including TNBC [84,87]. However, most of this work has focused on
a subset of TNBC designated as “serine-synthesis dependent” in which
suppression of any of the SSP enzymes causes a significant proliferative defect.
However, there are cell lines in which serine synthesis is dispensable for cell
proliferation; yet they still upregulate SSP enzymes when compared to normal
breast tissue [87]. This increased expression of SSP enzymes, namely PSAT1, in
these serine synthesis-independent cell lines suggests that they may promote
tumorigenic properties beyond enhanced proliferation. Based on this, we sought
to determine if there was a metastatic role for PSAT1 in two defined serin

41

B

Relative Level
(Positive / Total Pixels)

A

***

0.6

**
*

0.4

***

0.2
0.0

Normal 1

2
3
Grade

Figure 5: PSAT1 expression increases with TNBC grade. A) Formalin-fixed
paraffin embedded tissue sections were examined by immunohistological
staining for PSAT1. Shown are two independent representative images (20X)
from either normal breast tissue or from different grades of TNBC from tissue
microarray core sections. B) Quantitation of PSAT1 staining demonstrates a
significant increase in expression in higher TNBC grade. Relative levels of
PSAT1 was determined from multiple normal (n = 7), grade 1 (n = 11), grade 2
(n = 14), and grade 3 (n = 14) independent TMA tissue sections. Quantification
is demonstrated as relative level (positive / total pixel) of PSAT1 expression and
shown are mean + SEM. * p < 0.01, ** p < 0.005, *** p < 0.0001.
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synthesis-independent TNBC cell models, MDA-MB-231 and HCC1806 [87]. We
first found differential expression of PHGDH and PSAT1 in both cell types. While
MDA-MB-231 cells predominantly expressed PSAT1 compared to low level of
PHGDH, HCC1806 cells exhibited similar levels of both SSP enzymes (Figure 6).
Consistent with previous reports [55], we found that loss of PSAT1, via either
stable shRNA or transient siRNA silencing, did not negatively affect cell
proliferation (Figure 7A&B, Figure 8A&B). Alteration in cell morphology, in part
due to changes in actin cytoskeleton rearrangement, can directly influence the
motile capability of tumor cells. To examine whether loss of PSAT1 affected
cytoskeleton structure and cell morphology, we performed phalloidin staining to
visualize the F-actin cytoskeleton structure. Upon suppression of PSAT1, MDAMB-231 cells exhibited changes in both F-actin cytoskeleton arrangement and
overall cell morphology compared to control cells (Figure 7C). In particular, there
was a reduction in the spindle-shaped morphology normally observed in these
TNBC cells and a disruption in the actin stress fibers (Figure 7C). These results
suggest that PSAT1 may be important for maintenance of cell morphology and
may contribute to other tumorigenic properties in the MDA-MB-231 cells,
particularly cell motility. To determine the relevance of PSAT1 loss on this cellular
function, we examined the migratory ability of MDA-MB-231 cells, by both wound
healing and Boyden chamber transwell assays. Both stable and transient
suppression of PSAT1 significantly decreased motility of MDA-MB-231 cells by
>50% in both experimental procedures (Figure 9A&B, Figure 10A&B). We next
investigated the invasive potential of those cells using the matrigel coated
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Figure 6: PSAT1 and PHGDH transcript and protein expression in
MDA-MB-231 and HCC1806 TNBC cell lines. A) Transcript levels of
PSAT1 and PHGDH was determined by RT-PCR. Data is presented
as change in CT values between PSAT1 or PHGDH and -actin (mean
+ SD). B) Western analysis of PSAT1 and PHGDH expression in both
the MDA-MB-231 and HCC1806 cell lines.
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Figure 7: Loss of PSAT1 does not affect proliferation but alters
appearance actin-cytoskeleton. A) Western blot analysis of PSAT1
expression in MDA-MB-231 cells selected for stable expression of control or
PSAT1-specific shRNA. B) Cell proliferation in control or PSAT1-shRNA MDAMB-231 cells. Data are represented as mean + SD of viable cell counts at 24
and 48 hours. Results were analyzed by 2-way ANOVA, p<0.0001 C)
Representative images of cytoskeleton F-actin filaments upon phalloidin
staining in both control and PSAT1 shRNA MDA-MB-231 cells. Note: Control is
the same in the PHGDH experiments
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Figure 8: SiRNA suppression of PSAT1 has no proliferative effect. A)
Representative western blot analysis demonstrating PSAT1 expression in MDAMB-231 transfected with control or PSAT1 specific siRNA. B) Cell proliferation
at 24 and 48 hours after transfection with control or PSAT1 siRNA. Data is
presented as viable cell counts and shown is mean + SD. Results were
analyzed by 2-way ANOVA.
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Figure 9: Loss of PSAT1 suppresses MDA-MB-231 motility and invasion
in vitro. A) Representative images of wound healing assays for both control
and PSAT1 silencing in MDA-MB-231 cell lines at 0 and 24 hours. Quantification
is demonstrated as % wound closure (mean + SD), p<0.0001 as determined by
one-way ANOVA with Tukey’s comparison test. B) Representative images for
migration assays for both control and PSAT1 suppressed cells. Quantification
is presented as area stained and shown are mean + SD, p=0.0079 as
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C)

Representative images of Matrigel invasion assays with both stable shRNA
MDA-MB-231 cell lines. Quantification is reported as area stained and
represented as mean + SD, p < 0.0001 as determined by unpaired t test. Note:
Controls are the same as those represented within the PHGDH experiments.
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Figure 10: SiRNA suppression of PSAT1 decreases motility of MDA-MB231 cells in vitro. A) Representative images of wound healing assays of MDAMB-231 cells with transient suppression of PSAT1. Quantification is presented
as % wound closure (mean + SD), p=0.0217 as determined by unpaired t test.
B) Boyden chamber migration assays were quantified as mean + SD area
stained, p=0.0139 as determined by unpaired t test.
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transwells and found that suppression of PSAT1 also significantly inhibited MDAMB-231 cell invasiveness (Figure 9C).
To determine if these results were unique to these cells or extend to other
serine synthesis independent cell systems, we examined the effects of PSAT1
suppression on HCC1806 cells that exhibit comparable PSAT1 and PHGDH
expression (Figure 6). Similar to the MDA-MB-231 cells, we observed no
proliferative defect upon transient loss of PSAT1 (Figure 11A&B). In addition,
changes in HCC1806 actin stress fibers and cell morphology as seen with
phalloidin staining was also comparable to the MDA-MB-231 cells upon PSAT1
suppression, wherein cells exhibited loss of elongated stress fibers (Figure 11C).
Consistent with these findings, the migratory ability of these cells was also
significantly inhibited in both the wound healing (Figure 12A) and Boyden chamber
migration assays (Figure 12B) upon PSAT1 suppression. Taken together, these
results suggest that while PSAT1 silencing does not adversely affect the
proliferative capacity of serine synthesis-independent TNBC cells, PSAT1 loss
does significantly inhibit TNBC motility and migration.
Suppression of PHGDH does not phenocopy the loss of PSAT1 on migratory
ability
Given the differential levels of PHGDH between these cell lines, this data
suggests that the function of PSAT1 in contributing to motility may be separate
from its primary role in serine synthesis. To more directly examine this, we tested
both MDA-MB-231 (low PHGDH) and HCC1806 (similar PHGDH expression to
PSAT1) in the cell motility and migration models under both stable and transient
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Figure 11: Suppression of PSAT1 in HCC1806 cells does not have an antiproliferative effect. A) Representative western blot of PSAT1 levels after
transient transfection of negative control or PSAT1 siRNA. B) Cell proliferation
measured via trypan blue exclusion at 24 and 48 hours. Data is shown as mean
+ SD of viable cell counts and analyzed by 2-way ANOVA, Control p=0.0004,
PSAT1 p=0.0061. C) Representative images of cytoskeleton F-actin filaments
upon phalloidin staining in both negative control and PSAT1 siRNA treated
HCC1806 cells.
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Figure 12: Decreased motility of HCC1806 cells upon suppression of
PSAT1. A) Representative wound healing assay images. Quantification is
presented as % wound closure and shown is mean + SD, p=0.005 as
determined by unpaired t test. B) Image of cell migration after 24-hours.
Quantification is presented as area stained and shown is mean + SD, p=0.02
as determined by unpaired t test.
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suppression of PHGDH. As PHGDH catalyzes the rate-limiting step in cellular
serine production, suppression of this enzyme will underscore the relevance of the
SSP for the inhibitory effects we observe. Similar to previous studies, we found no
significant effect on proliferation upon loss of PHGDH in the MDA-MB-231 cells
(Figure 13A&B and Figure 14A&B). Unlike our studies with PSAT1 silencing,
PHGDH suppression did not affect the cell morphology or the F-actin cytoskeletal
structure as observed by phalloidin staining (Figure 14C). We also observed no
significant inhibition in either the wound healing (Figure 15A and Figure 16A) or
Boyden chamber migration assays (Figure 15B and Figure 16B), contrary to our
PSAT1 studies.
Alternatively, we also investigated PHGDH function in the HCC1806 cells
to demonstrate that these effects are not dependent simply on the dysregulation
of the serine synthesis pathway. Similar to MDA-MB-231 cells, suppression of
PHGDH did not affect HCC1806 proliferation (Figure 17A&B), F-actin cytoskeletal
arrangement compared to control cells (Figure 17C), nor inhibit the migratory
ability of these cells as observed in wound healing (Figure 18A) or Boyden
chamber migration (Figure 18B). These results demonstrate that suppression of
PHGDH does not phenocopy the inhibitory effects on these metastatic
characteristics that results upon PSAT1 silencing. This suggests that promotion of
the metastatic characteristics seen in serine synthesis-independent TNBC is
selective for PSAT1, which may be driven through a function unrelated to its role
in de novo serine production.
Suppression of PSAT1 inhibits experimental metastasis
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Figure 13: PHGDH is dispensable for MDA-MB-231 proliferation in vitro. A)
Representative western blot analysis demonstrating PHGDH expression in
MDA-MB-231 cells stably expressing control or PHGDH specific shRNA. B) Cell
proliferation at 24 and 48 hours with or without PHGDH expression. Data is
presented as viable cell counts and shown are mean + SD for both control and
PHGDH shRNA. Results were analyzed by 2-way ANOVA, Control p<0.0001,
PHGDH p=0.0057. Note: Controls are the same as those represented within the
PSAT1 experiments.
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Figure 14: SiRNA suppression of PHGDH in MDA-MB-231 cells has no effect on
in vitro proliferation. A) Representative western blot analysis demonstrating PSAT1
expression in MDA-MB-231 transfected with control of PHGDH specific siRNA. B) Cell
proliferation at 24 and 48 hours after transfection with control or PHGDH siRNA. Data
is presented as viable cell counts and shown is mean + SD. Results were analyzed by
2-way ANOVA, p<0.0001. C) Representative images of F-actin filaments after
phalloidin staining in control or PHGDH siRNA treated MDA-MB-231 cells.
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Figure 15: PHGDH is dispensable for MDA-MB-231 motility in vitro. A)
Wound healing assays twenty-four hours post-scratch. Data is demonstrated
as % wound closure and shown are mean + SD, p=0.9810 as determined by
one-way ANOVA. B) Representative images for Boyden chamber migration
assays. Quantification is presented as area stained (mean + SD), p=0.6477 as
determined by one-way ANOVA. Note: Controls are the same as those
represented within the PSAT1 experiments.
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Figure 16: SiRNA suppression of PHGDH in MDA-MB-231 cells has no
effect on motility or migration. A) Representative images of wound healing
assays of MDA-MB-231 cells with transient suppression of PHGDH.
Quantification is presented as % wound closure (mean + SD), p=0.2284 as
determined by unpaired t test. B) Boyden chamber migration assays were
quantified as mean + SD area stained, p=0.6160 as determined by unpaired t
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Figure 17: Loss of PHGDH does not affect HCC1806 proliferation. A)
Western blot analysis for PHGDH expression in HCC1806 cells after transient
transfection of control or PHGDH siRNA. B) Cell proliferation at 24 or 48 hours,
which is presented as viable cell counts (mean + SD). Results were analyzed
by 2-way ANOVA, Control p=0.0011, PHGDH p<0.0001. C) Representative
images of phalloidin stained F-actin filaments upon PHGDH suppression in
HCC1806 cells.
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Figure 18: Loss of PHGDH does not suppress HCC1806 motility or
migration potential. A) Representative images and quantification of wound
healing in HCC1806 cells. Data is presented as % wound closure and shown
are mean + SD, p=0.0754 as determined by unpaired t test. B) Boyden chamber
migration assays of HCC1806 cells with or without PHGDH. Quantification is
demonstrated as area stained (mean + SD), p=0.9563 as determined by
unpaired t test.
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To further investigate the potential role of PSAT1 in TNBC metastasis, we utilized
an established mouse model of experimental metastasis entailing TNBC lung
nodule formation after tail-vein injection (Figure 19A) [99]. Sixty days postinjection, we found a significant decrease in the number metastatic foci from MDAMB-231 cells lacking PSAT1 compared to mice injected with control cells (Figure
19B&C). We also found that the no injection mice did not develop tumor nodules
during the course of this experiment (Figure 19B). To ensure that the decrease
observed was not due to a loss of anchorage-independent growth, we examined
both control and PSAT1 silenced cells for the ability to grow in soft agar. We found
that loss of PSAT1 does not affect anchorage-independent growth of these cells
(Figure 20), supporting that loss of PSAT1 inhibits the metastatic potential of
TNBC in vivo.
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Figure 20: Suppression of PSAT1 does not affect anchorageindependent growth of MDA-MD-231 cells. A) Soft agar colony
formation assays of MDA-MB-231 cells stably expressing control or
PSAT1-specific shRNA. Shown are representative images of colonies
two weeks after plating from two independent experiments. B)
Quantification of soft agar assays. Data points are individual
experiments. Statistical analysis not performed as n=2.
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Discussion
In this report, we demonstrate that PSAT1 expression increases in higher grades
of TNBC. Unlike PHGDH, no genetic amplifications have been observed for
PSAT1 and elevated levels are the result of oncogenic pathways that are activated
as TNBC progresses. Multiple studies have previously demonstrated that
activating transcription factor 4 (ATF4) can control PSAT1 expression. ATF4 has
been shown to regulate PSAT1 in several different cancer types, including breast
cancer [46-49]. Importantly, in all tumors examined, ATF4 activation increases
expression of not only PSAT1 but also enzymes within the entire serine synthesis
pathway, including PHGDH and PSPH. As this is not selective for PSAT1
expression, as we have found in the MDA-MB-231 cells, this suggests other
regulatory mechanism(s) in TNBC that may be directly controlling PSAT1.
Within breast cancer, the transcription factors TAZ/YAP have been shown
to have higher activity in basal breast cancer subtype and to selectively induce
expression of PSAT1 in TNBC, specifically in the MDA-MB-231 cell line [60]. TAZ
expression is activated by the overexpression of the transcription factors Twist and
Snail [61]. This increased TAZ/YAP expression/activity has been correlated with
high histological grade breast cancer [61] as well as the promotion of oncogenic
transformation, enhancing tumorigenic properties, induction of cancer stem celllike activity and resistance to breast cancer drug therapies [100]. TAZ/YAP have
also been linked to increased metastatic capability in breast cancer [101]. In
addition, PSAT1 has also been shown to be induced by mTOR and be under the
regulation of the PI3K/Akt/mTOR pathway in breast cancer [62]. This pathway has
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been demonstrated to increase as breast cancer progresses with the highest
expression levels correlating with higher grade mammary tumors [102]. The
PI3K/Akt/mTOR pathway has also been highly associated with metastasis [102].
Taken together, multiple pro-tumorigenic pathways that mediate breast cancer
progression converge to increase PSAT1 expression that then may contribute to
the metastatic potential of TNBC.
We now show that suppression of PSAT1 in two defined serine synthesisindependent TNBC cell lines does not affect cell proliferation, yet, there is a
significant reduction in the in vitro metastatic capabilities of cell migration and
invasion due, in part, to alterations in F-actin cytoskeletal rearrangement and cell
morphology. Despite substantial PHGDH expression in a representative cell type
(HCC1806), this anti-metastatic effect seems to be selective for PSAT1 as PHGDH
suppression did not phenocopy loss of PSAT1. Further, PSAT1 contribution to
metastatic activity extended in vivo as protein suppression significantly inhibits
tumor nodule formation without disrupting the anchorage-independent growth of
these cells. As the tail-vein injection experimental model is limited in its
assessment of the entire metastatic cascade, particularly tumor cell escape from
a primary tumor, future examination of effects of PSAT1 loss in metastatic potential
from primary orthotopic tumors will be necessary to fully assess its function in
TNBC metastasis. Yet, these results suggest that PSAT1 may have an alternate
function in contributing to TNBC metastasis that is separate from its role in serine
synthesis.
It is important to note that these studies were carried out in TNBC cell types
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that have been designated as independent of de novo serine synthesis. While
expressing SSP enzymes, there is little to no metabolic flux through the SSP in
these cells, thereby necessitating a requirement for external serine for cell
proliferation. Conversely, it is well documented that there are TNBC cell lines and
patient tumors that are designated as serine synthesis-dependent. This subset
exhibits extremely high expression of PHGDH primarily due to genetic
amplifications. This drives increased flux through the SSP and allows for growth in
serine lacking conditions. Yet, even in serine complete conditions, suppression of
PHGDH or PSAT1 causes a significant reduction in cell proliferation in vitro due to
disruptions in glutaminolysis and nucleotide production [49,87]. In addition,
suppression of PHGDH, or the use of PHGDH inhibitors, have been shown to have
a detrimental effect on the growth of these tumors in vivo [86,87].
While serine synthesis-dependent tumor cells are sensitive to PHGDH
inhibitors, these compounds had no effect on serine synthesis-independent cell
types [86] and furthermore did not affect serine flux within this subset [87].
Consistent with these results, suppression of PSAT1 or PHGDH also did not affect
the proliferative capacity in the MDA-MB-231 cells in our studies [55,87].
Conversely, others have also demonstrated that overexpression of PSAT1 in other
independent cell types was able to increase proliferation and metastatic capability
[49]. Whether these effects were directly due to increased de novo serine synthesis
is unclear but supports a role for PSAT1 in promoting cell metastasis. These
previous findings coupled with our results demonstrating the metastatic inhibitory
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effects upon suppression of PSAT1 indicate a selective role for PSAT1 and not a
result of dysregulation of de novo serine production.
While these results suggest an activity for PSAT1 apart from serine
synthesis, its pro-metastatic function(s) in these cell types is unclear. There have
been several mechanisms proposed for non-canonical functions of PSAT1. For
example, in esophageal cancer, PSAT1 acts upstream of Akt that controls
downstream targets of GSK-3B and snail, which work to promote tumor
progression and enhance metastatic characteristics [72]. In non-small cell lung
cancer, it has been suggested that PSAT1 inhibits the degradation of cyclin D1,
which leads to an alteration in the Rb-E2F pathway [81]. However, despite these
potential non-canonical activities of PSAT1, decreased PSAT1 generally resulted
in loss of cell proliferation. This is not evident in our systems and suggests another
yet unknown function towards metastatic potential. Alternatively, Yang et al
postulates that TAZ/YAP’s regulation of PSAT1 is driven by a need to generate αketoglutarate in order to feed into the TCA cycle. They found that the serineindependent MDA-MB-231 cell line exhibits a high level of TAZ/YAP and are
designated as glutamine dependent [60]. This observation from Yang et al
combined with the implications of TAZ/YAP in metastasis indicates that this might
be a mechanism in which PSAT1 is contributing to the metastatic characteristics
of TNBC. In addition, the observed disruption in actin fibers upon suppression of
PSAT1 indicates that PSAT1 may contribute particularly to metastatic potential by
maintenance of cytoskeleton structure in promoting cell motility.
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Given the extent of PSAT1 expression across TNBC, even within subsets
not dependent on de novo serine synthesis, suggests that it may serve an alternate
function. These studies support a non-canonical role as loss of PHGDH did not
phenocopy PSAT1 suppression with regards to metastatic potential. Continued
work will be necessary to define whether PSAT1 functions in a similar manner in
additional TNBC cell types and the mechanisms by which PSAT1 supports TNBC
metastasis. Yet, despite the uncertainty of these mechanism, we believe that
PSAT1 is an appealing potential therapeutic target for TNBC patients; particularly
in suppressing metastatic spread.
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Extended Results and Discussion
In addition to the PHGDH suppression experiments that were done, we also
performed metastatic characteristics assays in the presence of exogenous serine
(Figure 21). Although the culture media for MDA-MB-231 cells contain 400uM
serine, we wanted to ensure that serine did not become limiting in our studies and
that our results are truly independent of a requirement for de novo serine synthesis
and utilization. We observed that the addition of exogenous serine (2.5mM) did not
rescue the PSAT1 suppression phenotype in either our wound healing (Figure 21)
or our migration assays (Figure 22). Since addition of exogenous serine was
unable to rescue this phenotype these data further suggests that PSAT1
contributes to TNBC metastasis independent of its role in serine synthesis.
Thus, to address the non-canonical function of PSAT1 that we observed in
these studies, we have preliminarily attempted to identify potential binding partners
of PSAT1 that could contribute to its anti-metastatic function. Database analysis
revealed several potential binding partners of PSAT1 that were identified through
large high throughput interaction screens. Two proteins that may influence this
metastatic

phenotype

are

of

particular

interest.

Tissue

inhibitor

of

metalloproteinases 2 (TIMP2), when expressed and active, typically inhibits tumor
growth, invasion, and metastasis via its inhibition of the matrix metalloproteinases
(MMPs) [103]. However, there have been reports of TIMP2 having multiple roles
and that in breast cancer there is evidence to support TIMP2’s involvement in
promoting proliferation, protecting against apoptosis, and correlating to poorer
progression-free survival [103] The contradictory roles of TIMP2 as both a
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Figure 21: Exogenous serine does not rescue PSAT1 suppression on cell
motility. Representative images of wound healing at 24 hours post scratch with or
without the addition of 2.5mM exogenous serine for the MDA-MB-231 cells transfected
with shRNA against control, PSAT1, or PHGDH. Data analyzed by one-way ANOVA,
**** p<0.0001, ** p=0.0035.
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Figure 22: Exogenous serine does not rescue effect of PSAT1 suppression
on cell migration. A) Representative images of Boyden chamber migration assays
24 hours post seeding with or without the addition of exogenous serine for the MDAMB-231 cells transfected with shRNA against control, PSAT1, or PHGDH. B)
Quantification of migration assays under normal serine conditions. Data analyzed
by one-way ANOVA, p=0.0021. C) Quantification of migration assays with 2.5mM
Serine. Data analyzed by one-way ANOVA, p=0.0264.
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correlator with low recurrence and poorer prognosis [104] could possibly be due to
its interacting partners. To confirm an interaction between PSAT1 and TIMP2, I
performed a co-immunoprecipitation assay (Figure 23) and found an association
between PSAT1 and TIMP2. It is plausible that the interaction of TIMP2 and
PSAT1 interferes with the ability of TIMP2 to inhibit MMPs and thus may promote
a pro-metastatic phenotype. However, upon loss of PSAT1, the TIMP2-PSAT1
interaction is abolished and TIMP2 is able to inhibit the MMPs and thus result in
the inhibition of the metastatic characteristics. Further studies to evaluate this
mechanism include endogenous co-immunoprecipitation studies to confirm the
interaction between PSAT1 and TIMP2. In addition, MMP activity assays would
also be performed utilizing both control and PSAT1 suppressed cells in order to
determine if PSAT1 suppression, and potentially loss of PSAT1-TIMP2 interaction,
has an effect on MMP activity.
A second potential interacting protein suggested was ras responsive
element binding protein 1 (RREB1). This protein’s drosophila homolog, hindsight
(HNT), has been shown to be involved in collective cell migration, the regulation of
cell adhesion, and to play a part in cell morphology [105]. These affects were
shown to occur via the JNK and Stat pathways. Additionally, it was shown in breast
epithelial cells that the expression of RREB1 was required for cell spreading and
migration as suppression of RREB1 did not affect cell viability but rendered the
cells immobile [105]. Thus, in an alternative mechanism, the dramatic differences
that we observed on cell morphology and migration upon PSAT1 suppression
could be attributed to a loss of the interaction between PSAT1 and RREB1. Either
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of these mechanisms may be valid means by which PSAT1 is contributing to the
metastatic characteristics of TNBC independent of its metabolic activity. Further
work would need to be done to fully investigate PSAT1’s role as it may relate to
these pathways.
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CHAPTER 3
PHOSPHOSERINE AMINOTRANSFERASE 1 (PSAT1) AND THE SERINE
SYNTHESIS PATHWAY ALTERS SENSITIVITY TO 4-HYDROXYTAMOXIFEN
TREATMENT IN ESTROGEN-RECEPTOR POSITIVE BREAST CANCER
Introduction
Breast cancer is the most common cancer that afflicts US women [3].
Importantly, breast cancer is not a singular disease, but is characterized by several
different histological subtypes that have now been identified. Estrogen receptor
positive breast cancer (ER+BC) is the most common breast cancer subtype [3]
and it accounts for 65% to 75% of all breast cancer cases [3]. ER+BC has a higher
incidence rate in older white women living in more western countries, like the
United States [7]. ER+ tumors express the estrogen receptor and the
growth/proliferation of these tumors are driven by estrogens binding to the
estrogen receptor and promoting transcription of pro-proliferative genes [10]. As
these tumors are reliant upon this estrogen-driven growth, therapies that target the
estrogen signaling pathway have become successful treatment options for patients
and much of the decline in mortality associated with breast cancer is credited to
their success [3].
All endocrine therapies target portions of estrogen signaling through
different mechanisms. The first clinical endocrine therapy, Tamoxifen, was
originally classified as an anti-estrogen because it functions as an estrogen
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antagonist in the breast, however, in other tissues it has agonistic properties [10].
It has thus been reclassified as a selective estrogen receptor modulator (SERM).
Tamoxifen can function on both estrogen receptor α (ERα) and estrogen receptor
β (ERβ) [106]. When tamoxifen is bound to ERβ it acts as a pure antiestrogen,
however, when tamoxifen is bound to ERα it can act as a partial agonist [106].
Tamoxifen’s primary mechanism of action in the breast is through competition with
estrogens binding to the estrogen receptor that results in the inhibition of the
estrogen driven pro-proliferative transcription program [12,13]. In addition to
binding to the estrogen receptor, tamoxifen has also been demonstrated to recruit
corepressors to the estrogen response elements in the promoters of estrogen
receptor target proteins as an additional mechanism of inhibition [106].
Fulvestrant, ICI, is considered a pure antiestrogen that exhibits no agonistic
activity [10,107]. Fulvestrant is also classified as a selective estrogen receptor
degrader (SERD) [9]. Fulvestrant differs from tamoxifen in its mechanism of action
as fulvestrant binds to the estrogen receptor and increases protein degradation
resulting in attenuation of the estrogen driven pro-proliferative transcriptional
program [12]. Fulvestrant also has a higher binding affinity for ER compared to
tamoxifen and is a more potent inhibitor of cell proliferation [107]. Fulvestrant is
often given to patients that have had disease progression following tamoxifen
treatment [10]. Fulvestrant can be used as a second line treatment because it has
been shown to have no cross-resistance with tamoxifen [107].
Despite numerous effective therapeutic options for patients with ER+BC
and a better patient prognosis, there are more deaths linked to ER+BC than any
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other subtype [11]. This is largely attributed to resistance to endocrine therapy,
which can be classified as either innate or acquired resistance. Innate, or de novo,
resistance relates to patients that have no initial response to endocrine therapy
[11]. Acquired resistance includes patients that initially respond to endocrine
therapy but then experience disease recurrence or progression [11]. Clinically, the
issue of endocrine resistance affects between 10% and 15% of all patients within
five years of diagnosis [22]. By 15 years following diagnosis, it is estimated that
30% of ER+BC patients will become resistant to endocrine therapies [22].
With the potential for endocrine resistance to affect 30% of all ER+BC
patients, there is an increased need to identify genes that may promote loss of
response to these therapeutic options. One of the genes that has been linked to
endocrine resistance is phosphoserine aminotransferase 1 (PSAT1) [82]. PSAT1,
along with phosphoglycerate dehydrogenase (PHGDH) and phosphoserine
phosphatase (PSPH) comprise the serine synthetic pathway. PSAT1 has been
implicated in numerous different cancer types as contributing to proliferation,
resistance, metastasis and has been implicated in breast cancer resistance to
endocrine therapy [49,57,58,65,72,81,82,97]. In these initial reports concerning
PSAT1 in breast cancer, it was determined that the expression of the PSAT1
transcript correlated to poorer progression-free survival in ER+ patients that were
treated with tamoxifen with the PSAT1 correlation being the most significant [82].
This was later confirmed at the protein level [97] and this study also suggested an
increase in PHGDH expression in tamoxifen insensitive breast cancer [97].
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Together, these results suggest a potential metabolic requirement for SSP acting
in promoting endocrine resistance.
In this report, we examine the clinical relevance of PSAT1 and PHGDH in
tamoxifen-resistant ER+BC and using in vitro models seek to determine if
sensitivity to tamoxifen treatments or antiestrogens can be altered by manipulation
of PSAT1 expression.
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Methods and Materials
Chemicals
(Z)-4-Hydroxytamoxifen was obtained from Sigma (H7904) and was
dissolved in 100% pure Ethyl Alcohol (Sigma – E7023). ICI 182,780 (Fulvestrant)
was obtained from TocrisBioscience (CAS No: 129453-61-8) and was dissolved in
dimethyl-sulfoxine (Fisher BioReagents – BP231). Concentrated stock solutions
were prepared, aliquoted and stored at -20°C for a period of 30 days. Diluted
working stocks were prepared fresh for each application.
Cell Culture
MCF-7 cells were purchased from ATCC. LCC9 and LY2 cells were
provided by Dr. Carolyn Klinge under an approved material transfer agreement
from Dr. Robert Clarke [108,109]. All cells were cultured in IMEM supplemented
with 5% FBS and gentamicin. All cells were incubated at 37° in 5% CO 2.
Plasmid Construction and Transfections
Human PSAT1 was generated from cDNA prepared from the LCC9 cell line.
RNA was extracted using the RNeasy kit (Promega) and 1mg of RNA was used to
produce cDNA using the reverse transcriptase kit (Thermo) with random primers.
Primers homologous to the 5’ and 3’ ends of the mature RNA encoding for PSAT1
were adapted to include restriction sites for ECOR1 (5’) and BAMH1 (3’).
Polymerase chain reactions were performed to amplify PSAT1 from LCC9 cDNA
preparation. PCR products were separated via gel electrophoresis and bands
corresponding to the correct PCR product were excised from the gel and purified.
PSAT1 fragments underwent restriction digest with ECOR1 and BAMH1 and then
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were ligated into the pcDNA3 vector that was similarly digested. Ligations were
then transformed and grown on LB agar plates with ampicillin. Isolated colonies
were cultured in LB broth and ampicillin for 24 hours and plasmids were isolated
via the Qiagen Miniprep kits. Plasmids, encoding either PSAT1 gene or empty
vector were verified by sequencing. Plasmids were then transfected into the MCF7 cell line using the Polyplus jetPRIME reagent according to manufacturer’s
protocol and clonal selection for PSAT1 expression was performed using
geneticin.
siRNA and shRNA Transfections
PSAT1 shRNA and Control shRNA were purchased from Sigma. ShRNAs
were transfected into LCC9 cells using the Polyplus jetPRIME reagent according
to manufacturer’s protocol. Clonal selection for gene silencing was performed
using puromycin. The sequences for the shRNA and siRNA species are as follows:
PSAT1

shRNA:

5’-

CCGGGCACTCAGTGTTGTTAGAGATCTCGAGATCTCTAACAACACTGAGTG
CTTTTTG-3’,

Control

shRNA:

5’-

CCGGCAACAAGATGAAGAGCACCAACTCGAGTTGGTGCTCTTCATCTTGTT
GTTTTT-3’, PHGDH RNAi: 5’-CGACAGGUUGCUGAAUGA-3’, non-targeting pool
RNAis: 5’-UGGUUUACAUGUCGACUAA-3’, 5’-UGGUUUACAUGUUGUGUA-3’,
5’-UGGUUUACAUGUUUUCUGA-3’, 5’-UGGUUUACAUGUUUUCCUA-3’.
Immunoblot Assays
Whole-cell lysates were prepared in IP Lysis Buffer (Pierce) containing
protease and phosphatase inhibitors. Proteins were separated on 10% SDS-
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polyacrylamide gels and transferred to PVDF. Membranes were blocked with 5%
non-fat dry milk in TBS-T and subsequently probed with 1:1000-fold dilution of antiPSAT1 (Proteintech, 10501-1-AP) or anti-PHGDH (Sigma HPA021241) antibodies
for 16 hours at 4°. Washed membranes were then incubated with 1:5000 dilution
of HRP-conjugated anti-rabbit or anti-mouse secondary antibodies. Protein
detection was done by exposure to ECL Prime chemiluminescent reagent (GE
Healthcare). Protein loading was assessed using anti-β-actin antibody (Sigma,
A2228). Densitometry was performed via ImageJ.
Stable Isotype Resolved Metabolomics (SIRM)
MCF7 or LY2 cells were cultured in glucose-free IMEM supplemented with
5% dialyzed serum and 1g/L 13C6 – glucose (Sigma) for 48 hours. Metabolism was
quenched via exposure to cold acetonitrile and cell metabolites were extracted
using

an

acetonitrile/chloroform/H2O

mixture.

Polar

metabolites

were

subsequently lyophilized and analyzed by Liquid Chromatography Mass
Spectrometry (LCMS) in collaboration with the Resource Center for Stable Isotype
Resolved Metabolomics Core facility at the University of Kentucky.
Treatments and Response
Cells were treated with either 4-hydroxytamoxifen (4-OHT) or ICI 182,780
(ICI) for a period of four days [110]. Treatment response was measured by
FluoReporter Blue Fluorometric dsDNA Quantitation Kit (Molecular Probes F2962). In brief, cells were plated at 5,000 (MCF-7) or 2,500 (LCC9) cells per well
on day 0. On day 1 cells were treated with indicated concentrations of either 4OHT or ICI. On day 4 the plates were collected and analyzed according to
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manufacturer’s protocol. Treatment responses were calculated by percent
decrease in fluorescence compared to the vehicle control.
Quantitative-Real Time Polymerase-Chain Reaction
MCF-7 or LCC9 cells were collected and total RNA was isolated using the
RNeasy Mini Kit (Qiagen). One milligram of RNA was converted to cDNA using the
High-Capacity

RNA-to-cDNA

kit

(appliedbiosystems)

according

to

the

manufacture’s protocol. Samples were then analyzed for qPCR via the TaqMan
Fast Advanced (appliedbiosystems) system with human probes for PSAT1
(Hs00795278_mH), PHGDH (Hs00198333_m1), and ACTB (Hs01060665_g1).
Kaplan Meier Analysis
Retrospective analysis of specific gene expression on patient survival was
performed by Kaplan-Meier analysis on de-identified patient clinical data obtained
from either an IRB-approved institutional biorepository [111] or within the online
database KM Plotter (kmplot.com) [112]. ER+BC patients treated with tamoxifen
or any endocrine therapy were stratified for differential PSAT1 or PHGDH
expression [113]. The hazard ratio (HR) with 95 % confidence intervals and the
logrank p value are indicated.
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Results
Clinical relevance of PSAT1 in ER+ patients treated with tamoxifen
It has been previously observed that PSAT1 transcript and protein levels
correlated with a poorer progression-free survival in ER+ patients treated with
tamoxifen [82,97]. We initially validated these prior studies in two separate patient
cohorts, including an institutional clinical population and individuals within the KM
Plotter database. All patients presented with ER+BC and had undergone
tamoxifen treatment as the sole endocrine therapy. In agreement, analysis of both
patient cohorts revealed a negative correlation between higher PSAT1 expression
and disease-free survival (Figure 24A) or relapse-free survival (Figure 24B).
These results, as well as the previous studies, suggest that PSAT1 may be
involved in tamoxifen resistance of ER+BC patients.
Manipulation of PSAT1 expression can alter sensitivity to tamoxifen therapy
Prior studies have established in vitro models used to investigate the
mechanisms that drive endocrine sensitive breast cancer to endocrine resistance
[114]. One model system utilizes the sensitive MCF-7 ER+ cell line and its resistant
derivatives. These derivative cell lines were generated by exposing parental MCF7 cells to increasing concentrations of endocrine therapies over an extended
period of time (Figure 25A). Acquired from our collaborator, Dr. Carolyn Klinge,
we employed this system to assess the contribution of PSAT1 and the SSP in
general to tamoxifen sensitivity. We initially found that there was differential
expression of PSAT1 between the resistant (LCC9 and LY2) and parental (MCF7) lines (Figure 25B). Transcript and protein analysis showed increasing levels of
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Figure 24: Clinical relevance of PSAT1 in Tamoxifen treated ER+BC. A)
Disease-free survival of ER+ patients treated with tamoxifen stratified by above
(n=33) or below (n=32) the median PSAT1 expression. Kaplan-Meier analysis was
performed from previous transcriptomic analysis on a patient cohort within an
institutional biorepository. B) Kaplan-Meier analysis of patient outcomes was done
using KM Plotter database. Relapse-free survival of ER+ patients treated with
tamoxifen stratified by low (n=73) or high (n=37) PSAT1 expression.
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Figure 25: Differential PSAT1 expression between sensitive and resistant
cell lines. A) Schematic summarizing the in vitro model system used in these
studies. B) Representative western blots demonstrating the differential
expression between the endocrine sensitive MCF-7 parental line and the
endocrine resistant derivatives (LCC9 and LY2). Densitometry analysis was
performed using ImageJ. C) Transcript levels, represented as ΔCT, of PSAT1
between the different cell lines.
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PSAT1 in the resistant cell types (Figure 25 B and C). Importantly, the MCF-7
sensitive cell line exhibits no PSAT1 expression as compared to the resistant lines.
To determine whether the increase in enzyme expression corresponds to elevated
SSP activity, we used stable isotope resolved metabolomics (SIRM) to evaluate
glucose carbon incorporation into de novo serine production (Figure 26A). Using
the LY2 cells, as they demonstrated the greatest enzyme expression, we found
elevated SSP in the resistant cell line as evidence of greater levels of

13C

carbon

from glucose into serine (m+3 serine), while activity in the MCF-7 line was below
detectable limits (Figure 26B).
This differential expression of SSP enzymes, particularly PSAT1, between
sensitive and resistant lines indicates that SSP activity may influence tamoxifen
sensitivity. To investigate this potential metabolic consequence, we chose to alter
PSAT1 levels in these cell models as endocrine sensitive MCF-7 cells do not
express this SSP enzyme. First, PSAT1 was overexpressed in the MCF-7 cells
(Figure 27A-B) to determine its effect on 4OHT response compared to the
parental cells. Overexpression of PSAT1 in the MCF-7 cell line reduced the
sensitivity of these cells at two different concentrations of 4-OHT (Figure 27C).
Exposure to 100 or 500nM 4OHT led to 40-45% reduction in MCF-7 cell
proliferation. Yet, PSAT1 expressing cells had reduced sensitivity to 4OHT (2225% decrease respectively). Conversely, the contribution of PSAT1 to 4OHT
resistance was also examined under loss of PSAT1 in the resistant LCC9 cell line.
Using stable shRNA, PSAT1 was suppressed in the LCC9 cells (Figure28A) and
resulted in a sensitization to 4OHT treatment (Figure 28B). Taken together, these
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Figure

27:

Overexpression

of

PSAT1

reduces

sensitivity

to

4-

hydroxytamoxifen. A) Representative western blot demonstrating the level of
overexpression of PSAT1 in the MCF-7 cells. B) Transcript levels demonstrating
the extent of PSAT1 overexpression in the MCF-7 cells. p=0.0005 as determine
by unpaired t test. C) Response to 4OHT, measured as percent decrease in cell
proliferation, for both the MCF-7 empty vector and MCF-7 PSAT1
overexpression cell lines. p=0.0006 100nM 4OHT, p=0.0002 500nM 4OHT as
determined by 2-way ANOVA with Tukey’s comparison test.
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A

Figure

B

28:

Suppression

of

PSAT1

increases

sensitivity

to

4-

hydroxytamoxifen. A) Representative western blot demonstrating the
suppression of PSAT1 in the LCC9 cell line. B) Response to 500nM 4OHT,
measured as percent decrease in cell proliferation, for both the LCC9 shControl
and LCC9 shPSAT1 cell lines. p=0.0001 as determined by unpaired t test.
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results indicate that PSAT1 and SSP activity may be a contributing factor in the
resistance to tamoxifen of ER+ patients.
Clinical relevance of PHGDH in ER+ patients treated with tamoxifen
As part of the prior study on PSAT1 protein expression in clinical ER+BC
samples, the authors also suggested that PHGDH might also be contributing to
resistance in ER+ patients treated with tamoxifen [97]. This was attributed to the
finding of increased expression of PHGDH in the tamoxifen treated patients that
exhibited poorer clinical outcomes. However, no statistical or experimental
analysis were performed to validate this potential relevance of PHGDH. Using KM
plotter, we sought to determine if this observation could be associated with patient
survival. Analyzing the same patient cohort used for PSAT1 (Figure 24), we found
that patients with higher PHGDH expression also had significantly poorer relapsefree survival compared to patients with low PHGDH expression (Figure 29).
Similar to PSAT1, suppression of PHGDH also sensitized LCC9 endocrine
resistant cells to 4OHT treatment (Figure 30).
Clinical correlation involving SSP enzymes and in vitro sensitivity to
endocrine therapy is selective for tamoxifen
Endocrine therapies encompass several different approaches to suppress
estrogen signaling. Beyond 4OHT, the pure antiestrogen Fulvestrant and
aromatase inhibitors are frequently used in the clinic. Inevitably, patients will also
become resistant to these endocrine therapies as well. We next wanted to
determine whether SSP enzymes contributed to resistance to other endocrine
treatments. Within in vitro experiments, we examined the effect of PSAT1
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Figure 29: Clinical relevance of PHGDH in ER+ patients treated
with tamoxifen. KM Plotter was used to determine relapse-free
survival of ER+ patients treated with tamoxifen that was stratified by
low (n=486) or high (n=184) PHGDH expression.
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hydroxytamoxifen. A) Representative western blot demonstrating the
suppression of PHGDH in the LCC9 cell line. B) Response to 500nM 4OHT,
measured as percent decrease in cell proliferation, for both the LCC9 siRNA
Control Pool (siCP) and LCC9 siPHGDH cell lines. p=0.0197 as determined by
unpaired t test.
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suppression on sensitivity to ICI in LCC9 cells, as the LCC9 cell line is also
resistant to ICI treatment [109]. We treated either control or PSAT1 suppressed
cells with different concentrations of ICI and found no significant difference in cell
proliferation (Figure 31A). To determine if this result extended to clinical data, we
analyzed a patient cohort that was inclusive of ER+BC patients treated with any
endocrine therapy. We then stratified these patients based on transcript levels of
either PSAT1 (Figure 31B) or PHGDH (Figure 31C). When all endocrine therapies
are included, significant association between high expression of the SSP enzymes
and relapse-free survival is lost (Figure 31), contrary to what we observed with
tamoxifen as the sole therapy (Figure 24, Figure 29). These data suggest that the
contribution of PSAT1 or PHGDH to endocrine resistance may be limited to
tamoxifen therapy.
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Figure 31: Correlation between SSP enzymes and relapse-free survival and in
vitro sensitivity to endocrine therapy is selective for tamoxifen. A) LCC9 control
of PSAT1 suppressed cells in response to ICI treatment at different concentrations.
Response measured as percent decrease in cell proliferation. p>0.9999 50nM ICI,
p=0.9774 100nM ICI, p>0.9999 500nM ICI as determined by 2-way ANOVA with
Tukey’s comparison test. B) Relapse-free survival of ER+ patients treated with all
endocrine therapies stratified by low (n=121) or high (n=60) PSAT1 expression. C)
Relapse-free survival of ER+ patients treated with all endocrine therapies stratified
by low (n=498) or high (n=244) PHGDH expression. Kaplan-Meier analysis
performed with KMPlotter database.
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Discussion
In this chapter we have demonstrated that both PSAT1 and PHGDH are
correlated with poorer relapse-free survival in ER+ patients that were solely treated
with tamoxifen. This agrees with previously published findings that implicated
PSAT1 in tamoxifen resistance [82,97]. Furthermore, we showed that manipulation
of PSAT1, either via overexpression in a tamoxifen sensitive model or suppression
in a tamoxifen resistant model, can alter sensitivity to 4OHT treatment. In addition,
loss of PHGDH was also shown to alter sensitivity to 4OHT. These data indicate
that the serine synthetic pathway contributes to tamoxifen resistance. Additionally,
these effects seem to be selective for tamoxifen as both in vitro and clinical data
failed to show any correlation between expression of serine synthetic enzymes and
sensitivity to ICI or with inclusion of other endocrine therapies with respect to the
KM analysis.
We speculate that the differences that we have observed between 4OHT
and ICI treated cells could be related to their different mechanisms of action.
Tamoxifen is a selective estrogen receptor modulator and its primary mode of
action is through the binding to the estrogen receptor, competing with estrogens,
resulting in inhibition of the estrogen driven pro-proliferative transcription program
[12,13]. There is also evidence that tamoxifen can function independently of
binding to the estrogen receptor via induction of transforming growth factor-β
(TGF-β) and through reduction of circulating insulin-like growth factor I (IGF-I) [13].
Fulvestrant is a “pure”-antiestrogen or a selective estrogen receptor downregulator [12]. Fulvestrant binds to the estrogen receptor, impairs its dimerization,
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and increases protein degradation and turn-over. This results in the complete
attenuation of downstream estrogen signaling [12]. Importantly, in tamoxifen
treated conditions, the estrogen receptor remains expressed; in contrast, during
fulvestrant treated conditions there is a loss of the estrogen receptor [12]. This
combined with our results suggest that tamoxifen resistance mediated by PSAT1
and PHGDH may be reliant upon either the maintenance of the estrogen receptor,
its co-activators, or one of its gene targets. While the requirement for maintenance
of ER as it relates to PSAT1 and PHGDH-mediated resistance would need further
investigation, there is literature evidence to support this notion. MYC is a known
target of estrogen receptor signaling and its function as well as its role in endocrine
resistance requires maintenance of the ER [115].
Although these results suggest there might be a requirement for ER
maintenance, the mechanism(s) by which PSAT1 and PHGDH are contributing to
tamoxifen resistance is unclear. It could be through oncogenic activation of the
SSP by proteins such as MYC, which has already been suggested to activate
transcription of PSAT1 and PHGDH [52] and both (SSP and MYC) have been
implicated in endocrine resistance [82,97,116]. Or the SSP-mediated resistance
could be related to one of the metabolic consequences of de novo serine
synthesis. Previous literature has suggested that glutamine is required for the proproliferative estrogen-driven signaling cascade in ER+BC [115]. It has also been
suggested that while uptake of glutamine is independent of estrogen signaling, this
process may also require maintenance of ER expression [115], similar to what our
results suggest for PSAT1 and PHGDH-mediated resistance. Additionally, PSAT1
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is responsible for the second processing step of intracellular glutamine as it
converts

glutamate

to

α-ketogluterate

[28],

which

connects

glutamine

consumption, the SSP, and endocrine resistance to maintenance of ER
expression. Alternatively, epigenetic changes have also been proposed as a
mechanism for tamoxifen resistance [22]. These changes include increases in
hypomethylated promoter regions of oncogenic genes and hypermethylated
promoter regions of tumor suppressors [22]. There is also evidence to suggest that
in breast cancer the ER cofactors are under epigenetic control and that
dysregulation of these cofactors is correlated with resistance to tamoxifen therapy
[22]. As stated, PSAT1 and PHGDH are both members of the serine synthetic
pathway along with PSPH. This pathway diverges from the glycolytic pathway at
3-phosphoglycerate for de novo synthesis of serine [28]. Downstream, serine can
be used in one carbon metabolism to generate s-adenosyl-methionine (SAM)
[117]. SAM is the methyl donor for the methylation of nucleic acids, proteins, and
lipids and there has been evidence to support that the levels of serine dictate the
levels of SAM [117].
Given the literature and our results, we hypothesize that PSAT1 and
PHGDH are contributing to tamoxifen resistance through de novo serine synthesis
by both processing of glutamine and the downstream generation of SAM and
subsequent epigenetic changes but further investigation into this area would be
needed to confirm that this is the mechanism in which the serine synthetic pathway
is contributing to resistance (Figure 32). In addition, it would be interesting if
treatment with PHGDH inhibitors [86,118] would be able to recapitulate the effects
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Figure 32: Model of SSP contribution to endocrine resistance. This model
represents the suggested mechanisms by which PSAT1 and PHGDH are
contributing to tamoxifen resistance in ER+BC. In sensitive conditions there is
an inhibition of estrogen signaling and low expression of ER target genes. In
resistant condition there is increased ERα signaling, despite a tamoxifen (4hydroxytamoxifen) occupied ER, and increased expression of ER target genes.
One target gene, cMYC, is increased in resistant conditions and has been
shown to increase expression of PSAT1 and PHGDH but it is unknown if this
increase is dependent on ERα. The upregulation of SSP enzymes can
contribute to resistance via either glutamine dependence to fuel the TCA cycle
or through increased one-carbon metabolism to produce SAM.
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of genetic suppression of PHGDH and PSAT1 that we have observed in this
chapter. Those results might suggest a combination therapy that may reduce
resistance and prolong efficacy to tamoxifen therapy.
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CHAPTER 4
CONCLUSION
In summary, this body of work has demonstrated that PSAT1 contributes to
the progression of breast cancer in the contexts of TNBC metastasis and ER+BC
tamoxifen resistance. We have shown that suppression of PSAT1 is able to
diminish metastatic characteristics in vitro and that loss of PHGDH does not
recapitulate these results. We have also shown that suppression of PSAT1 inhibits
tumor nodule formation in an in vivo model of experimental metastasis and that
this inhibition is not due to a loss of tumorgenicity. The results from our TNBC
studies suggest a non-canonical role for PSAT1 that selectively inhibits the
metastatic characteristics of “serine synthesis-independent” TNBC (Chapter 2).
We have also demonstrated a correlation between higher expression levels
of PSAT1 and poorer progression-free survival in two distinct ER+BC patient
cohorts. In addition, we have shown that manipulation of PSAT1 and PHGDH can
alter sensitivity to tamoxifen treatment in an established sensitive and resistant
breast cancer cell model system. Our work indicates that these results are due to
changes in de novo serine synthesis as clinically high expression of PHGDH also
correlates with poorer progression-free survival and there is increased flux of
glucose to serine in endocrine resistant cells. We also demonstrated that these
effects of the SSP enzymes appear to be selective for 4OHT treatment as
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disruption of the SSP through PSAT1 loss did not alter fulvestrant sensitivity in two
tamoxifen resistant cell lines. In addition, all clinical significance regarding inverse
correlation of PSAT1 and PHGDH with relapse-free survival in ER+BC was lost
upon inclusion of patients treated with any endocrine therapy (Chapter 3).
My data suggests that the functional roles of PSAT1 as it contributes to
either metastasis or resistance varies. In the TNBC component of this dissertation,
PSAT1 is acting independently of its role in serine synthesis as we established that
PHGDH suppression did not recapitulate PSAT1 suppression. However, in the
ER+BC portion of this dissertation it seems that the contribution of PSAT1 to
tamoxifen resistance is associated with its role in serine synthesis as clinically both
PSAT1 and PHGDH significantly correlated with poorer progression-free survival.
These results, while conclusive, leave some remaining questions. Primarily, how
does the expression of a single protein, PSAT1, promote two distinct processes
(metastasis or endocrine resistance) via two separate mechanisms (canonical vs.
non-canonical)? In addition, what dictates either canonical or non-canonical
function of PSAT1 and are these functions mutually exclusive? Lastly, is this
phenomenon driven exclusively by the proteome differences between TNBC and
ER+ tamoxifen resistant breast cancer subtypes?
It is known that there are subtype-specific expression differences for PSAT1
in other cancer types. It has been shown that PSAT1 is higher in certain ovarian
cancer subtypes and that PSAT1 expression can be used as a biomarker to
determine the subtype of ovarian cancer a patient has [78]. In addition, PSAT1
expression also varies in thyroid cancer subtypes [57]. PSAT1 expression in breast
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cancer is also known to vary by subtype. PSAT1 protein expression is greater in
ER- compared to the ER+BC [84,87,94,95]. The lack of expression of PSAT1 in
ER+BC is mainly due to hypermethylation of the PSAT1 promoter within this
subtype [94]. This suggests that there might be an ER-dependent silencing of
PSAT1 within the ER+ subtype that is lost in tumors that are ER-. Previous
literature would also suggest that this potential ER-dependent regulation is specific
for PSAT1 and not a regulatory mechanism for the SSP as the differences in
promoter methylation are specific for PSAT1 [82,94,95] and that both ER+ and ERtumors express PHGDH [87].
The role of PSAT1 in metastasis that we have defined in this body of work
is in a specific subset of TNBC that is “serine-synthesis independent”. This subset
allowed us to determine if there was a PSAT1 specific role in metastasis that was
independent from its role in de novo serine synthesis. My data suggests that there
is a selective role for PSAT1 in breast cancer metastasis. Other groups have also
found an association between PSAT1 and metastasis that was not found with other
members of the SSP [85]. This specific association between PSAT1 and
metastasis has also been observed in several other cancer types. This has been
observed in nasopharyngeal carcinoma [65] where higher expression of PSAT1
correlated with poorer local recurrence-free and distant metastatic-free survival.
Additionally,

higher

PSAT1

expression

was

correlated

with

metastatic

characteristics [57,58] as well as lymph-node metastasis and distant metastasis in
esophageal squamous cell carcinoma [72]. While in the report on nasopharyngeal
carcinoma no mechanism was suggested, the findings in esophageal squamous
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cell carcinoma also indicated a non-canonical function of PSAT1 in order to
upregulate the expression/activity of GSK3β and Snail that promoted metastatic
characteristics in their in vitro studies [72].
In addition, there have been numerous accounts of de novo serine
synthesis implicated in resistance. This has been demonstrated in multiple
myeloma where higher activity of SSP enzymes was observed in resistant cell
types and suggested that expression of the SSP enzymes could serve as a
biomarker for Bortezomib resistance [69]. There has also been a link established
between SSP and resistance to the BRAF inhibitor Vemurafenib [68]. This was
observed in melanoma, pancreatic cancer, and non-small cell lung cancer in which
SSP enzyme expression was higher in resistant cell types which resulted in
increased proliferation [68]. Our work, as well as previous work [82,97],
demonstrates that there is a role for the SSP in resistance to tamoxifen in ER+BC
as higher expression of both PSAT1 and PHGDH correlate to poorer progressionfree survival.
However, the question remains is the canonical and non-canonical function
of PSAT1 mutually exclusive and more interestingly, would the metastatic
characteristics of endocrine resistant cells be solely affected by suppression of
PSAT1? While these experiments were not performed as a part of this work, there
is some literature to suggest that these functions are not mutually exclusive and
that PSAT1 still contributes to metastasis independently of function in de novo
serine synthesis. Studies completed in models of colon cancer demonstrate that
there is increased activity of the SSP in colon tumors compared to normal colon
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tissue [74], especially in patients that were resistant to chemotherapies [75].
However, PSAT1 was the singular most upregulated protein in colorectal
carcinoma patients [75] and specifically increased PSAT1 expression correlated
with metastasis in resistant patients [73]. We have previously discussed that
PSAT1 correlates with tamoxifen resistance [82] and that upregulation of PHGDH
was also found in tamoxifen resistant patients [97] as this was the foundation for
the studies completed in chapter 3. However, we did not address metastasis in our
ER+BC studies. Metastasis and its correlation to PSAT1 and PHGDH expression
in the ER+ tamoxifen resistant setting has been previously studied [97]. In part,
they found that PSAT1 and not PHGDH correlated with metastasis in ER+ patients
who are tamoxifen resistant [97]. Both of these findings indicate that PSAT1 can
simultaneously function within serine synthesis to promote tamoxifen resistance,
as we have demonstrated, and independently contribute to metastasis as
observed in our TNBC experiments.
The question of what dictates the function of PSAT1 remains unknown. This
could be related to how PSAT1 expression is regulated and/or whether or not
downstream effectors of PSAT1 that are responsible for either metastasis or
endocrine resistance are present. Loss of miRNA-dependent suppression of
PSAT1 resulted in increased protein expression and correlated with metastatic
disease in two different cancer types [57,58]. Increased demand for serine and the
resultant one-carbon metabolism products upregulate PSAT1 and de novo serine
synthesis as a means of ensuring tumor cell survival whilst undergoing therapeutic
treatment leading to the resistant phenotypes observed. In both of these instances,
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the upregulation of PSAT1 and the resultant function was determined by a
combination of events that included additional steps and/or proteins, thus PSAT1
may be the driver of metastasis and/or endocrine resistance but the determination
of which process occurs could be decided by which downstream pathways ensure
the survival of the cancer cell.
Together, my data suggest that the metastatic phenotype is related to a
function of PSAT1 that is independent from its role in serine synthesis. It also
underscores that therapy resistance is reliant upon the serine synthetic pathway
which is consistent with previous findings that altered methylation patterns
correlate with resistance and that de novo synthesized serine is used in onecarbon metabolism. Despite differences in functional roles and reliance on serine,
this body of work has established that PSAT1 contributes to the progression of
breast cancer through promoting metastasis in TNBC and resistance to tamoxifen
in ER+BC.
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